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Abstract

PHYSIOLOGICAL AND SUBJECTIVE EFFECTS OF PROTONATED NICOTINE
LIQUIDS IN TOBACCO USERS.
By Alisha N. Eversole, B.A.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
at Virginia Commonwealth University
Virginia Commonwealth University, 2021
Major Director: Thomas Eissenberg, Ph.D.
Professor of Psychology
Department of Psychology and Center for the Study of Tobacco Products
Electronic cigarettes (ECIGs) produce an aerosol by heating a liquid that often contains
nicotine. The nicotine can be protonated, potentially making the aerosol easier to inhale than
freebase nicotine. This study’s purpose was to determine, in inhaled tobacco product users, the
effects of three concentrations of protonated nicotine aerosolized at two different power settings
(in watts).
Twenty-two participants completed six sessions that varied by liquid nicotine
concentration (10, 15, or 30 mg/ml protonated nicotine) and device power (15 or 30 W).
Participants took 10 puffs from each product and then used each product for 60 minutes ad
libitum. Plasma nicotine concentration, puff topography, and subjective effects were measured.
Findings from the present study suggest that liquid protonated nicotine concentration and
device power setting influence ECIG nicotine delivery, user behavior, and subjective effects
associated with use of ECIG devices containing protonated nicotine. For example, increases in
one or more than one of these factors leads to increases in plasma nicotine concentration. This
effect emphasizes the need to consider several factors in order to effectively regulate the nicotine
delivery of ECIGs.
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Physiological and Subjective Effects of Protonated Nicotine Liquids in Tobacco Users.
Tobacco smoking is the leading cause of preventable death worldwide, and in the United
States an estimated one in five deaths is attributed to cigarette smoking each year (USDHHS,
2014). Life expectancy of cigarette smokers is more than ten years shorter than individuals who
never smoked (Jha et al., 2013). Eight million people worldwide die each year from tobaccorelated diseases (World Health Organization, 2019). Combustible cigarette smoking causes many
illnesses including cancer, heart disease, stroke, lung diseases, chronic obstructive pulmonary
disease, and diabetes (USDHHS 2014). Cigarette smokers also are at increased risk for
tuberculosis, pneumonia, and impaired immune function (USDHHS, 2014). In the United States,
more than 16 million people live with a tobacco-related disease (USDHHS 2014). The estimated
economic toll of tobacco-related death and disease in the United States is more than $300 billion
(USDHHS, 2014; Xu et al., 2015). Despite the well-documented deleterious health effects of
smoking, 13.7% of adults, 5.8% of high-school students, and 2.3% of middle-school students are
current (i.e., past 30-day) cigarette smokers (Creamer et al., 2019; Wang et al., 2019). Efforts
aimed at reducing tobacco smoking and exposure to tobacco smoke are of utmost importance to
the quality of life of the American population and to the American economy.
Tobacco smoke contains over 2,500 chemical constituents, including many known
carcinogens (CDC, 2010) that can be found in mainstream and secondhand tobacco smoke
(Öberg et al., 2011). Inhalation of tobacco smoke directly exposes the user to carcinogenic
chemicals and other toxicants and primarily is responsible for the well-documented increases in
death and disease that occur in tobacco smokers. The negative health effects of exposure to these
toxicants have been established (Buran & Samet, 2020; CDC, 2010; Öberg et al., 2011). The
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detrimental health effects of tobacco products are among the primary motivators for efforts
aimed at tobacco use prevention (especially among youth) and cessation.
In 2015, 68% of combustible tobacco cigarette smokers reported that they want to stop
smoking completely, and 55.4% attempted to quit (Babb et al., 2017; USDHHS, 2020).
However, only 7.4% of tobacco smokers successfully quit in 2017 (USDHHS, 2020). Nicotine, a
constituent of tobacco and a psychomotor stimulant drug, produces dependence in a majority of
users and makes smoking cessation difficult (Prochaska & Benowitz, 2019), in part due to
aversive abstinence symptoms (e.g., craving, irritability, insomnia) that accompany abrupt
smoking cessation (Hughes & Hatsukami, 1986; Robinson et al., 2019). Nicotine binds as an
agonist at nicotinic acetylcholine receptors, and this action in the brain primarily is responsible
for the drug’s psychoactive and dependence-producing effects (Benowitz, 2010; Leonard &
Bertrand, 2001). Neuroadaptive changes occur in response to repeated nicotine exposure; after
abrupt smoking/nicotine cessation, this neuroadaptation causes decreased activation of the
dopaminergic system, leading to aversive abstinence symptoms (Benowitz, 2010; Prochaska &
Benowitz, 2019). One recommended first-line treatment of tobacco dependence is counseling
combined with nicotine replacement therapy (NRT; i.e., nicotine patch, nicotine gum) (Lindson
et al., 2019). The administration of medicinal nicotine is safer than administration of nicotine via
combustible cigarettes and helps to prevent relapse to smoking by alleviating aversive
nicotine/tobacco abstinence symptoms (Germovsek et al., 2020; Wadgave & Nagesh, 2016) and
blunting the effects of a concurrently administered cigarette (Foulds et al., 1992). Clinical trials
have established this combination as the most effective intervention leading to cessation
(Hartmann-Boyce et al., 2018a), and it can produce a significant increase in the likelihood of
complete and sustained smoking cessation (Cahill et al., 2013; Hartmann-Boyce, et al., 2018a).
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Though the increase in likelihood of successful cessation is statistically significant,
approximately 7% of smokers who use the recommended medicinal cessation aids successfully
quit using tobacco products (Hartmann-Boyce et al., 2018a). Due to the small proportion of
smokers who successfully quit using NRT and other pharmacologic smoking cessation aids, the
search for more effective treatment options persists.
In 2006, a new tobacco product entered the United States marketplace: electronic
cigarettes (ECIGs). ECIGs have been studied as a potential cessation aid and/or a reduced harm
product, based on the ability of some of these products to deliver nicotine with fewer
carcinogenic chemicals compared to cigarettes (Gentry et al., 2019; St. Helen et al., 2020).
Additionally, public health concerns have been raised regarding ECIG use as, at least in the US,
approximately 23% of previously nicotine-naïve youth and young adults (age 14-30) have
initiated tobacco use with ECIGs (Soneji et al., 2017). As highlighted below, youth ECIG
initiation is a public health risk because ECIGs are capable of delivering nicotine to blood and
brain (Voos et al., 2019), and nicotine exposure can harm the developing brain and cause
dependence (England et al., 2015; NASEM, 2018). Also, the risk profile associated with longterm ECIG use is uncertain (Callahan-Lyon, 2014; Franck et al., 2016), and youth who initiate
tobacco use with ECIGs are approximately three times more likely to initiate cigarette smoking
relative to youth who do not use ECIGs (Soneji et al., 2017). The sections below provide an
overview of ECIGs as a tobacco product class, and then describe the ways they may be used, the
influence of device power, liquid nicotine concentration and nicotine form on nicotine delivery,
and the present study.
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ECIGs: an overview
Electronic cigarettes heat a liquid that often contains nicotine to create an inhalable
aerosol. Patented in 2003 (Hon, 2003), ECIGs have increased in popularity in recent years (King
et al., 2018) and have evolved considerably from their original design (Voos et al., 2019). One
way of characterizing this evolution is to describe ECIGs by “generations” of products (e.g.,
Breland et al., 2018), in which the original generation are classified as disposable “cig-a-likes”
(because they look like a combustible cigarette); the second generation includes a rechargeable
battery and, often, a reusable cartridge/tank that holds the liquid; the third generation involves
modular or “mod” components such as interchangeable heating elements and other features that
allow the user to control device power, and the most recent generation involves ECIGs that use
small, disposable liquid-filled pods (that also hold the heating element) and so are called “pod
based” or “pod mod” ECIGs. Research involving each generation of ECIGs reveals the
characteristics of the devices (e.g., electrical power; Wagener et al., 2017; Talih et al., 2019), the
liquids used in them (Behar et al., 2017; Goniewicz et al., 2014; Omaiye et al., 2019), and the
nicotine delivery profile of some device/liquid combinations (e.g., Dawkins & Corcoran, 2014;
Harvanko et al., 2020a; Wagener et al., 2017; St. Helen et al., 2016; Hiler et al., 2020; Vargas et
al., 2020). While first generation ECIGs delivered very little or no nicotine (Bullen et al., 2010;
Vansickel et al., 2010), other more modern devices such as third generation “mods” and fourth
generation “pod mods” have the potential to deliver as much or more nicotine than a combustible
cigarette (Hiler et al., 2020; Yingst et al., 2019).
In addition to studying device characteristics and nicotine delivery profile, several
clinical trials have examined ECIGs as a smoking cessation aid, revealing, at least in some cases,
a modest improvement in cessation rates relative to NRT (Hajek et al., 2019; Walker et al.,
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2020). While these clinical trial results suggest some efficacy, increasing use of ECIGs by young
people (Gentzke et al., 2019), particularly those who never smoked combustible cigarettes
(Soneji et al., 2017), is alarming and a potential threat to public health (Maziak, 2020). Also
alarming is that, as ECIG products have evolved, ECIG devices have increased in their electrical
power output (Farsalinos et al., 2014; Wagener et al., 2017) that may lead to greater user toxicant
exposure (El-Hellani et al., 2018) and ECIG liquids have increased in their nicotine
concentration (Walley et al., 2019). This increase in liquid nicotine concentration has been
accompanied by a shift from the more aversive free-base form of nicotine to the less aversive
protonated form (Jackler & Ramamurthi, 2019). Together, increased nicotine concentration and
decreased aversiveness may increase the likelihood of ECIG-induced nicotine dependence
(Huang et al., 2019). Unfortunately, little is known about how increased device power, greater
liquid nicotine concentration, and nicotine form (i.e., freebase versus protonated) influence the
nicotine delivery profile of the aerosol produced from an ECIG. Each of the topics discussed
briefly above are detailed in the following sections.
What are ECIGs?
In general, an ECIG consists of four components: a source of electrical power (usually a
battery), a reservoir to hold a liquid (e.g., “cartridge”, “tank”, or “pod”), and a heating element or
“coil” that is sometimes a separate component and other times is an integrated part of the
reservoir. The liquid that is placed in the reservoir often contains nicotine along with propylene
glycol, vegetable glycerin, and flavoring agents. When the battery is activated, either by puffing
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on the device or pressing a button, electrical power flows through the coil to heat the liquid and
the inhalable aerosol is produced.
First generation or “cig-a-likes” are designed to look like a cigarette and often are
disposable and cannot be refilled with liquid. The heater generally is activated when the user
puffs on the mouth end. At least as originally marketed, cig-a-likes often failed to deliver
nicotine effectively. For example, in a study of 32 ECIG-naive combustible cigarette smokers,
participants took ten puffs (30 second inter-puff interval, or IPI) during each of four study
conditions: an own brand cigarette, a cig-a-like ECIG with a 16 mg/ml liquid, a different cig-alike ECIG with an 18 mg/ml liquid, and an unlit combustible cigarette (Vansickel et al., 2010).
The lit combustible cigarette condition was a positive control that served to show typical nicotine
delivery of a combustible cigarette under normal conditions. The unlit combustible cigarette was
a negative control that served to control for the act of inhaling the ten puffs without any nicotine
delivery. When participants used their own brand of cigarette, mean plasma nicotine
concentration increased significantly from 2.1 ng/ml (SD=0.3) at baseline to 18.8 ng/ml
(SD=11.8) immediately after the 10th puff. This nicotine delivery profile of a combustible
cigarette is similar to that observed in other studies after similar puffing conditions (e.g., 15-20
ng/ml; Breland et al., 2002; Cobb et al., 2010). Mean plasma nicotine peak change from baseline
was not significant in either the 16 mg/ml condition (0.5 ng/ml) or the 18 mg/ml condition (1.4
ng/ml). No significant differences were observed when comparing mean plasma nicotine
concentration after 10 puffs in either of the ECIG conditions to 10 puffs from the unlit tobacco
cigarette. In another study of 23 experienced ECIG users, participants took 10 puffs (similar to
Vansickel et al., 2010, described above) during two study conditions: a first generation ECIG
and a second generation ECIG (Farsalinos et al., 2014). Both conditions in this study used the
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same 18 mg/ml ECIG liquid. When participants used the first generation ECIG, mean plasma
nicotine increased significantly from 2.8 ng/ml (SD=0.4) at baseline to 4.9 ng/ml (SD=0.5)
immediately following 10 puffs. When participants used the second generation ECIG, mean
plasma nicotine increased significantly from 2.5 mg/ml (SD=0.3) at baseline to 6.6 ng/ml
(SD=0.6) following 10 puffs. Mean plasma nicotine concentration was significantly greater when
participants used the second generation ECIG but were still lower than those obtained after
smoking a tobacco cigarette under similar conditions (e.g., Vansickel et al., 2010). Other clinical
laboratory studies of first generation ECIGs reported no significant nicotine delivery (Bullen et
al., 2010) or very little nicotine delivery (Dawkins & Corcoran, 2014; Nides et al., 2014).
Overall, compared to combustible cigarettes, cig-a-likes generally are not effective at nicotine
delivery.
Second generation ECIGs are typically larger than cig-a-likes and contain a refillable
reservoir (often called a cartridge or tank) that also contains the heating element which, in some
cases, can be replaced (Breland et al., 2018). Device power (a function of battery voltage and
heating element resistance) of second generation ECIGs is sometimes higher than that of cig-alikes. Typically, the nicotine used in these devices is available in similar concentrations (0 mg/ml
to ≈20 mg/ml; though sometimes slightly greater, up to ≈36 mg/ml) and form (freebase) as first
generation devices. Studies of cigarette smoke suggest that freebase nicotine (pH ≈9) is more
easily absorbed when compared to protonated nicotine (pH ≈6, El-Hellani et al., 2015; Pankow,
2001).
Second generation ECIGs sometimes deliver more nicotine when compared to first
generation devices (e.g., Farsalinos et al., 2014, described above). In a clinical laboratory study
using methods similar to Vansickel et al., 2010, 33 ECIG-experienced individuals completed
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four ECIG (“eGo” 3.3-V battery with a 1.5 Ohm coil, device power of 7.3 W) use conditions (10
puffs; 30 second IPI) that differed by the nicotine concentration of the liquid nicotine that was
placed into the ECIG cartridge: 0, 8, 18, or 36 mg/ml (Hiler et al., 2017). Plasma nicotine
“boost” (the difference that results when baseline nicotine concentration is subtracted from postpuffing nicotine concentration) differed significantly across the 0, 8, 18, and 36 mg/ml
conditions. In the 8 mg/ml condition, mean nicotine boost was 8.2 ng/ml (SD=7.8). As liquid
nicotine concentration increased, nicotine boost also increased; mean boost in the 18 mg/ml
condition was 13.0 ng/ml (SD=6.2) and in the 36 mg/ml condition was 17.9 ng/ml (SD=17.2).
When a similar liquid nicotine concentration was used in first generation devices (18 mg/ml; see
Vansickel et al., 2010 detailed above), nicotine delivery was not significantly greater than that of
an unlit cigarette. In this study using second generation devices, nicotine boost was significantly
greater in the 8, 18, and 36 mg/ml conditions when compared to the 0 mg/ml condition. Second
generation ECIGs can sometimes deliver nicotine to the user, and the amount of nicotine
delivered depends, at least in part, on the concentration of nicotine in the liquid that is placed
into the ECIG reservoir. Similar results have been observed in other studies involving second
generation devices (e.g., Wagener et al., 2017). The increased power and nicotine concentration
when compared to first generation devices may result in the observed increase in nicotine
delivery. Overall, reliable nicotine delivery can be observed in these second generation devices,
approaching the nicotine delivery of a combustible cigarette in some conditions (e.g., 36 mg/ml
nicotine in a ≈7 W device; 10 puffs with a 30 sec IPI).
Third generation ECIGs often have a larger battery (for longer use between charges) and
a larger tank (that holds more liquid) compared to previous generations (Breland et al., 2018).
These devices are also referred to as “mods,” or “box mods” due to the ability of the user to
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customize the power of the device as well as the concentration and form of liquid used (Breland
et al., 2018). In a study using similar methods described previously (Hiler et al., 2017; Vansickel
et al., 2010), the nicotine delivery profile of second and third generation ECIGs were compared
(Wagener et al., 2017). ECIG experienced users who reported using either a second or third
generation ECIG for > three months were recruited and used their preferred device for this study.
Nine second generation and 11 third generation users completed the study, and their personal
ECIG devices were used for an initial 5 minute, 10-puff bout (30 second IPI) followed by 115
minutes of ad libitum use. After 10 puffs, mean plasma nicotine concentration was significantly
less in the second generation group, at 7.3 ng/ml (SD=2.8), relative to the third generation group,
at 17.5 (SD=12.9). These differences are likely due to differences in liquid nicotine concentration
and device power. Indeed, second generation devices used in this study had mean liquid nicotine
concentration of 22.3 mg/ml (SD=7.5) and device power of 8.9 W (SD=1.9). Third generation
devices had a significantly lower mean liquid nicotine concentration of 4.1 mg/ml (SD=2.9), and
higher mean device power of 71.6 W (SD=50.0). Mean device power was approximately eight
times higher in the third generation group compared to the second generation group. This
difference in device power may be responsible for the increased nicotine delivery observed in
third generation devices, despite the observation that the third generation devices were filled with
a liquid that had a nicotine concentration that was significantly lower than the second generation
devices. Consistent with this suggestion, research from an aerosol research laboratory study
using a machine-puffing protocol reveals that, when all other factors are held constant,
increasing power by a factor of 2.5 (i.e., from 3 to 7.5 W) leads to a three- to four-fold increase
in nicotine emissions (Talih et al., 2015).
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In a study in which power was manipulated systematically (Hiler et al., 2020), plasma
nicotine again increased as device power increased. ECIG experienced users (N=32) used an
ECIG (4.5-V Kanger SUBOX; ECIG use similar to previously described studies, i.e., Vansickel
et al., 2010) for each of four study conditions that differed by device power and liquid nicotine
concentration (40.5 or 13.5 W; 3 or 8 mg/ml). In the 40.5 W+8 mg/ml condition, mean plasma
nicotine concentration increased significantly from 2.7 ng/ml (SD=2.6) at baseline to 10.2 ng/ml
(SD=8.2) following 10 puffs. In the 40.5 W+3 mg/ml condition, mean plasma nicotine increased
significantly from 2.5 ng/ml (SD=1.5) at baseline to 7.0 ng/ml (SD=5.0). In the 13.5 W+8
mg/ml, mean plasma nicotine increased significantly from 2.5 ng/ml (SD=1.9) at baseline to 7.1
ng/ml (SD=8.7), and in the 13.5 W+3 mg/ml, mean plasma nicotine concentration did not differ
significantly from baseline after 10 puffs. Mean plasma nicotine concentration in the 40.5 W+8
mg/ml condition was significantly higher than all other conditions after ten puffs. The systematic
manipulation of power and liquid nicotine concentration in this study shows that both power and
liquid nicotine concentration contribute to the nicotine delivery profile of ECIGs. Specifically, as
device power is increased, the nicotine delivery profile is increased; the same is true for liquid
nicotine concentration. Similar studies are consistent with these findings (e.g., Harvanko, et al.,
2020a). Overall, as with second generation devices, “mods” are capable of reliable nicotine
delivery, especially when device power is high; in such cases, their nicotine delivery profile
approaches that of a combustible cigarette (15-20 ng/ml; see Vansickel et al., 2010 above).
The most popular ECIG used in the United States is JUUL, a “pod mod” style device
(King et al., 2018; Vallone et al., 2019). These devices use disposable “pods” that combine the
heating element and liquid. Though JUUL is the most popular brand of pod mod, there are a
number of similar products commercially available, including disposable devices that do not fall
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under current federal flavor regulations (FDA 2019; Williams, 2019). Pod mod devices typically
have less power than third generation ECIGs (e.g., ≈8 W; Talih et al., 2019). The liquid nicotine
concentration is often high (50-60 mg/ml), and typically consists of protonated nicotine (Talih et
al., 2019) as opposed to liquids used in earlier generation devices which consists of freebase
nicotine. Freebase nicotine, as described above, can be aversive at high concentrations because it
is absorbed preferentially in the upper respiratory tract, leading to irritation (Henningfield et al.,
2004; Pankow, 2001). Protonated nicotine is a combination of the freebase that is chemically
bound with a proton from an acid (i.e., benzoic acid) which forms a salt. Nicotine salt is carried
with the aerosol generated by the ECIG past the upper respiratory tract and is deposited deep in
the respiratory tract. Therefore, the irritation from the freebase is largely attenuated, making
protonated nicotine less aversive at high concentrations (Pankow, 2001). Although freebase
nicotine is more easily absorbed (based on studies of tobacco cigarette smoke), protonated
nicotine allows the user to inhale a larger volume of high concentration nicotine aerosol, which
may lead to increased nicotine delivery (Brunnemann & Hoffmann, 1974; St. Helen et al., 2017).
In a study of experienced JUUL users, participants completed two 60-minute ad libitum
ECIG use periods (preferred flavor and tobacco flavor; Vargas et al., 2020). In the preferred
flavor condition, mean plasma nicotine increased significantly from 1.8 ng/ml (SD=0.4) at
baseline to 10.9 mg/ml (SD=1.5) following ECIG use. In the non-preferred flavor condition,
mean plasma nicotine increased from 2.02 ng/ml (SD=0.4) at baseline to 10.4 ng/ml (SD=1.6)
following ECIG use. In another study comparing JUUL and IQOS (a heated tobacco product that
is not considered an ECIG) in 18 cigarette smokers, participants took 10 puffs (30 second IPI)
from a product in each study condition: JUUL, IQOS, or own brand (OB) combustible cigarette
(Maloney et al., 2020). When participants used OB, mean plasma nicotine concentration
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significantly increased from 2.1 ng/ml (SD=0.2) at baseline to 20.4 ng/ml (SD=20.4) following
10 puffs. When participants used JUUL, mean plasma significantly increased from 2.2 ng/ml
(SD=0.7) at baseline to 9.8 ng/ml (SD=4.9) following 10 puffs. When participants used IQOS,
mean plasma nicotine significantly increased from 2.1 ng/ml (SD=0.2) at baseline to 12.7 ng/mL
(SD=6.2) following 10 puffs. Mean plasma nicotine concentration was significantly greater in
the OB condition, compared to the JUUL and IQOS conditions.
An additional study of dual users (ECIG users who also smoke combustible cigarettes)
examined the nicotine delivery profile of JUUL and combustible cigarettes following 5 minutes
of ad libitum use (Hajek et al., 2020). Maximum plasma nicotine concentration was achieved
during use (at 4 minutes) for both conditions. Mean maximum plasma nicotine concentration
(Cmax) for JUUL was 20.4 ng/ml (SD=15.0), and combustible cigarette Cmax was 19.2 ng/ml
(SD=17.6). This comparable nicotine delivery profile of JUUL relative to the combustible
cigarette condition may be attributed to familiarity with the device; in previous studies, the
nicotine delivery profile of JUUL was assessed in combustible cigarette smokers (e.g., Maloney
et al., 2020). In this study, participants had experience using ECIGs, and regularly used both
ECIGs and combustible cigarettes. ECIG-experienced individuals take longer puffs from ECIGs
than ECIG-naïve combustible cigarette users (Hiler et al., 2017) and longer puff duration leads to
more nicotine being emitted from the mouth-end of an ECIG (Talih et al., 2015). Pod mod
devices reliably deliver nicotine, though the nicotine delivery profile can be less than that of a
combustible cigarette after 10 puffs in ECIG-naïve individuals. However, the nicotine delivery
profile of pod mod devices may reach that of a combustible cigarette in users that are familiar
with the device, likely because these users take longer puffs. Similar studies have observed a
similar nicotine delivery profile in pod mod devices (e.g., Yingst et al., 2019; Wynne et al.,
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2018). Pod mod ECIGS are lower powered devices compared to third generation ECIGs, yet they
are able to deliver nicotine in similar ways. Their high nicotine delivery profile likely is due to
the high liquid nicotine concentration that users find less aversive to inhale because the nicotine
is in the protonated from. This combination of nicotine delivery and palatability, along with
marketing and product design, likely contributed to the rapid growth in popularity of pod mod
ECIGs (Huang et al., 2019; Ickes et al., 2020; Vargas et al., 2020).
Additionally, ECIG nicotine delivery profiles have been compared within generations,
revealing considerable heterogeneity. In a study comparing nicotine delivery across fourteen
different devices (including first, second, and third generation) characterized as “first generation”
and “advanced generation,” differences were observed within the “advanced” category (Yingst et
al., 2019). In this study, 14 ECIG users used their own devices (either first generation or
advanced generation with liquid nicotine concentration >12 mg/ml) for 30 puffs (20 second IPI).
Mean nicotine boost for first generation devices was 1.8 ng/ml (SD=0.9), compared to 10.8
ng/ml (SD=9.8) for advanced generation ECIGs. While some variability was observed for first
generation devices, visual inspection of the plasma nicotine figure (Figure 2 in Yingst et al.,
2019) reveals eight of the ten advanced generation ECIGs with nicotine boost less than 10 ng/ml
and two advanced devices resulting in nicotine boost over 20 ng/ml. Additionally, withingeneration variability was observed in a study described previously (Wagener et al., 2017).
Significant differences were observed between second and third generation devices, however
significant variability in mean plasma nicotine concentration was observed in the third
generation group, with a large standard deviation (12.9) around a mean of 17.5 that suggested
heterogeneity in nicotine delivery within this group of products. In both of these studies,
significant differences are observed between ECIG generations, but importantly, significant
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variability observed within generation may make nicotine delivery profile characterization by
generation an oversimplification.
While early ECIG devices were sometimes shown to deliver very little nicotine (Bullen et
al., 2010; Vansickel et al., 2010), other contemporary devices can deliver as much or more
nicotine than a combustible cigarette (Hajek et al., 2020; Hiler et al., 2017; Wagener et al.,
2017). These changes are important to monitor and understand thoroughly, and extant data make
clear that characterizations based solely on generation do not predict the nicotine delivery of a
device. Instead, understanding the influence of device characteristics and user behavior on
nicotine delivery can lead to a more robust understanding of these products, who uses them and
why, and the impact they may have on public health.
Who uses ECIGS and why?
Globally, the value of the ECIG market is $12.3 billion (only 1-2% of the global value of
the combustible cigarette market; Kennedy et al., 2017). The countries with the largest share of
the ECIG market are the United States, Russia, and Germany (Kennedy et al., 2017). In the
United States, 3.2% of adults and 20.8% of youth (under 18) reported past 30-day ECIG use in
2018 (Bao et al., 2020; Cullen et al., 2018). A dramatic increase in ECIG use has been observed
among youth in the United States, with an increase from 1.5% in 2011 to 20.8% in 2018 (Cullen
et al., 2018). Rates of ECIG use among adults have remained relatively stable, ranging from
3.7% in 2014 to 3.2% in 2018 (Bao et al., 2020). As previously noted, ECIGs have been
described as a public health advantage capable of increasing combustible cigarette smoking
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cessation rates (Hajek et al., 2019; Walker et al., 2020) as well as a threat to public health due to
increasing use by youth (FDA, 2018; Maziak, 2020).
ECIGs have been considered as a cessation aid or reduced harm product because of their
potential ability to deliver nicotine with reduced exposure to toxicants when compared to
combustible cigarettes (Goniewicz et al., 2017; Hartmann-Boyce et al., 2018b; St. Helen et al.,
2020). In a study using 2014 and 2015 data from the cross-sectional National Health Interview
Survey (NHIS) examining current and recently former smokers (smokers who quit during or
after 2010, N=15,532), a quarter of survey respondents (N=3739) had quit smoking at the time of
the survey (Giovenco & Delnevo, 2018). Among these former smokers, 10.3% were daily ECIG
users, compared to 3.3% daily ECIG users in the group of current smokers. Daily ECIG use was
reported in 5.1% of the entire sample, and within this group over half (52.5%; N ≈416) reported
that they quit smoking cigarettes in the last 5 years. Daily ECIG use was the strongest predictor
of prolonged combustible cigarette smoking abstinence in this study that involved self-reported
tobacco use behavior and no objective verification of smoking status. This study suggests that
daily ECIG use may increase the likelihood of successful cessation of combustible tobacco use.
In a study using data from Waves 1-3 (2013-2016) of the Population Assessment of
Tobacco and Health (PATH) longitudinal cohort study, reported ECIG use at Wave 1 was
examined as a possible predictor of reported abstinence from smoking combustible cigarettes at
Wave 2 and 3 (Kalkhoran et al., 2020). Among respondents who reported daily combustible
cigarette use at Wave 1, 22% were also daily ECIG users. Daily ECIG use at Wave 1 was
significantly associated with prolonged abstinence from combustible cigarette smoking at Waves
2 and 3. There was no significant association between non-daily ECIG use and prolonged
combustible cigarette smoking abstinence. Though these two studies give insight into the
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potential relationship between daily ECIG use and cessation of combustible cigarette smoking,
they do not provide evidence on the clinical efficacy of ECIGs as a combustible smoking
cessation aid. In a meta-analysis examining ECIG use and combustible cigarette smoking
cessation among adult combustible cigarette smokers, 20 studies with control groups were
examined (Kalkhoran & Glantz, 2016). The studies examined included 15 cohort studies, three
cross-sectional studies, and two clinical trials (both detailed below). Overall, ECIG use was
associated with a 28% decrease in odds of quitting cigarettes compared with those who did not
use ECIGs. Importantly, this decrease in odds is not consistent with individual results from a
number of studies. This inconsistency suggests that until data are examined together, the
observed benefit of ECIGs in combustible smoking cessation in individual studies may be an
overestimation.
Though controlled, prospective research on ECIG use as a combustible smoking
cessation aid is sparse, there are three relatively large-scale, double-blind, randomized controlled
trials (RCTs) that have examined the efficacy of ECIGs when used as a combustible smoking
cessation aid. In a 2013 RCT, 657 participants were randomly assigned to three groups, and were
given either: 21 mg nicotine patches (N=295, one per day; NRT), a 16 mg/ml ECIG (N=289), or
a placebo ECIG (N=73; containing no nicotine). Abstinence was verified via exhaled breath
carbon monoxide (CO) at six months post-quit day (Bullen et al., 2013). Behavioral support was
also offered via telephone and/or SMS from a national quitline. The ECIG used in this study was
a first generation ECIG, and four participants completed a testing procedure after one week of
ECIG use with the active device that contained the 16 mg/ml nicotine liquid. During this testing
procedure, plasma nicotine concentration increased from 2.1 ng/ml at baseline to a peak of 3.4
ng/ml after ten minutes of product use. The nicotine delivery observed in this testing period was
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similar to the nicotine delivery profile observed in other first generation devices (see Farsalinos
et al., 2014, detailed above), and an order of magnitude less than typically seen after 10 puffs
from a combustible cigarette (e.g., Vansickel et al., 2010). Overall, 78% (N=513) of participants
completed follow-up at six months. Abstinence at six months after quit day (verified by CO) was
7.3% in the 16 mg/ml ECIG group, 5.8% in the NRT group, and 4.1% in the placebo ECIG
group. No between-group differences were statistically significant. Thus, this study does not
provide evidence that ECIGs (with or without nicotine) are more or less effective than NRT for
combustible cigarette smoking cessation.
In an RCT published in 2019, 1124 participants were assigned randomly to one of three
groups: 21 mg nicotine patches (N=125, one per day; NRT), NRT plus an 18 mg/ml ECIG
(N=500), or NRT plus a placebo ECIG (N=499, containing no nicotine). Abstinence was verified
(via eCO) six months after quit day (Walker et al., 2020). Weekly behavioral support was
provided via phone for the first six weeks. The ECIG used in this study was a second generation
ECIG, paired with either 0 mg/ml or 18 mg/ml liquid nicotine concentration. Participants were
permitted to seek out new ECIGs or liquids if desired. During the trial, 15% of the NRT only
group had used an ECIG during the trial, and 11% of the NRT plus 0 mg/ml ECIG group had
switched to using an ECIG containing nicotine. Overall, 69% of participants completed followup at six months following their quit date. Among those participants, six-month abstinence rates
were 7% in the NRT plus 18 mg/ml ECIG group, 4% in the NRT plus 0 mg/ml ECIG group, and
2% in the NRT only group. Abstinence rates in the NRT plus 18 mg/ml ECIG group were
significantly higher than both the NRT plus 0 mg/ml ECIG group and the NRT only group.
These results suggest a small but reliable improvement in combustible cigarette cessation when
using a nicotine-containing ECIG in combination with NRT and six weeks of telephone
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counseling. Though these results suggest that using a second generation ECIG device paired with
NRT could increase the likelihood of successful combustible cigarette abstinence, the lack of
testing of the nicotine delivery profile of the device used and the high loss to follow-up rate
(31%) should be noted when considering the results observed in this study. Additionally, this
study involved the use of telephone counseling and NRT, neither of which are available at retail
venues where ECIGs are sold (i.e., “vape” shops), where most ECIG users purchase ECIG
products (Braak et al., 2019).
In an RCT published in 2020, 886 participants were randomly assigned to two groups
(ECIG, N=439, or NRT, N=447) and provided with either a second generation ECIG or their
preferred NRT product on their quit date (Hajek et al., 2019). The ECIG used in this study was a
“OneKit,” a beginner ECIG kit with instructions on how to use/refill the device. Specifically, this
device consisted of a 2.1-ohm atomizer and 650-mAh battery and included one bottle of 18
mg/ml nicotine liquid. 42 participants used a different ECIG that consisted of a 1.5-ohm atomizer
and 1000-mAh battery due to the discontinuation of the original “OneKit” during the trial.
Weekly one-on-one behavioral support provided by a clinician was offered for at least four
weeks. Overall, 78.8% of participants completed follow-up at one year after their quit date.
Among those participants, the 1-year abstinence rate in the ECIG group was 18.0%, compared to
9.9% in the NRT group. These results suggest ECIGs could be a more effective combustible
cigarette cessation aid than NRT, at least in the context of individualize counseling. These results
also suggest that using a second generation ECIG device could increase the likelihood of
prolonged successful combustible cigarette abstinence, though importantly, the nicotine delivery
profile of this ECIG was not tested. The loss to follow-up was comparable to other studies (i.e.,
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Bullen 2013 above), and this loss is important to consider when evaluating the efficacy of ECIGs
as a combustible cigarette smoking cessation aid.
Considering these three RCTs together, there is growing evidence for the potential
efficacy of at least some ECIGs when used as a combustible smoking cessation aid when they
are paired with cessation counseling (either via phone or individualized and in person) and,
perhaps, with NRT. Importantly, even the study with the greatest effect (Hajek et al., 2019)
reports a treatment failure rated of >80%. Clearly, additional RCTs are needed to establish under
what conditions and for whom ECIGs are effective as cessation aids. Such studies would be
most informative if the nicotine delivery profiles of the ECIG device/liquid(s) used were
established prior to participant enrollment and the ability of the device/liquid(s) to deliver
nicotine effectively was part of the rationale for inclusion of these products in the RCT. While
there is some evidence that ECIGs can help treatment-seeking, cigarette-smoking adults to quit
smoking, adult combustible cigarette smokers are, unfortunately, not the only group using
ECIGs.
As previously described, ECIG use among youth has increased dramatically, from 1.5%
in 2011 to 20.8% in 2018 (Cullen et al., 2019). During this same time period, combustible
cigarette use among youth has declined from 15.8% to 8.1% (Gentzke et al., 2019). This
increased prevalence in ECIG use is correlated directly with the marketing of pod mod devices
that contain protonated nicotine, including JUUL (a low-wattage device with a ≈60 mg/ml
nicotine concentration liquid containing 94% protonated nicotine; Talih et al., 2019). Pod mod
devices are especially popular with youth, likely due to a combination of marketing, design that
facilitates concealed use, and lack of aversive properties upon inhalation due to the use of
protonated nicotine (Glasser et al., 2021; Ickes et al., 2020; Pankow, 2001). As detailed in Figure
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1, as ECIG use has increased among youth, a public health threat emerges, particularly when
nicotine-naïve youth (or youth that otherwise would not have used tobacco products) begin to
use ECIGs. Indeed, evidence is emerging of nicotine-naïve youth using ECIG devices containing
protonated nicotine (Krishnan-Sarin et al., 2019). While ECIGs may provide a public health
benefit when used as combustible cigarette smoking cessation aids, increased popularity among
youth has the potential to negate any public health benefit by initiating nicotine dependence in
young people.
Past 30 day use of cigarettes and ECIGs, US
high school students (NYTS data)
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Figure 1. Past 30-day use of cigarettes and ECIGS in US high school students, 1998-2019.
Data taken from the National Youth Tobacco Survey (CDC).
In a cross-sectional survey study, 371 undergraduate university students reported reasons
for use of a protonated nicotine containing ECIG device (Ickes et al., 2020). Overall, 36% of
participants reported ever use of protonated, nicotine-containing ECIGs. Current (past 30-day)
use of these devices was reported by 21% of the sample. The two most popular reasons for use
among ever users were curiosity (95%), and “my friends use it” (81%). These reasons indicate an
awareness of the product and popularity with peers as primary motivators to initiate use of these
products. The most popular reasons for use among current users were: “ease of use” (91%),
“doesn’t smell bad” (87%), portability (85%), stress/relaxation (82%). These reasons suggest
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that maintained use of these products may be motivated by device characteristics and nicotine
dependence. While youth and young adults may initiate use of protonated nicotine containing
ECIGs due to the desire to experiment with a product they are aware of (likely through
marketing) and to fit in with their friends, the maintenance of use may depend on specific device
characteristics (ease of use, portability) and nicotine dependence (relief of stress/abstinence
symptoms). Considering these reasons for use makes clear that ECIGs containing protonated
nicotine may have created a user base of young people who might otherwise have avoided
combustible tobacco products and thus exposure to nicotine.
In a study of students from 4 Connecticut high schools in 2017, 875 students responded
that they had used at least one of the four ECIG generation devices (Krishnan-Sarin et al., 2019).
Mod devices were the most popular (71.2%) among ever users. Among current users, a pod mod
device containing protonated nicotine was the most popular (47.1%). Ever use of the protonated
nicotine containing pod mod device was not associated with other tobacco product use (e.g.,
cigarettes, cigars, cigarillos, hookah, or smokeless tobacco), suggesting that users of this type of
device may have been nicotine-naïve upon initiation of use. Current use of protonated pod mod
devices was associated with a higher socio-economic status (SES) when compared to those who
did not use this type of device. Interestingly, SES could also contribute to likelihood of other
tobacco product use, as lower SES previously has been established as a predictor of tobacco use
(Gilman et al., 2003; Mathur et al., 2013; Wang et al., 2018). In order to understand how initial
use of ECIG devices containing protonated nicotine may contribute to later use of other tobacco
products, the reasons for initial use in youth and young adult users must be explored.
Additionally, the relationship between ECIG use and subsequent use of other tobacco products
must be examined.
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In a longitudinal study of college-aged students, the relationships between ECIG use and
subsequent combustible cigarette use was examined (Spindle et al., 2017). Among those who
reported ever trying e-cigarettes at baseline (N=153), approximately a quarter (24.2%; N=37)
reported having tried cigarettes one year later. Ever ECIG users at baseline were over three times
more likely to report trying cigarettes one year later. This study demonstrates that ECIG use
could lead to an increase in the likelihood of combustible cigarette use. Similar results were
observed in a review of four longitudinal studies, where participants who reported ECIG use at
baseline were 3-5 times more likely to use combustible cigarettes at follow-up (12-15 months)
when compared to non-ECIG users (Chatterjee et al., 2018). These studies indicate that ECIG
use increases the likelihood of combustible cigarette smoking, an especially alarming result
considering the high rate of ECIG use in youth and young adults (detailed above). When
considering reasons for initiation and continued use of ECIGs, and the increased vulnerability to
use other tobacco products, youth ECIG use becomes an important public health consideration.
Evidence from individual studies suggests that ECIGs may benefit public health when
used to aid cessation of combustible cigarette smoking, though when data are examined together,
the use of ECIGs as a combustible cigarette cessation aid is associated with a decreased
likelihood of success (Kalkhoran & Glantz, 2016). The public health threat of ECIG use among
youth and young adults must also be considered. Especially imperative is the threat of ECIG use
in otherwise nicotine-naïve youth, and how that use may lead to nicotine dependence and later
use of combustible cigarettes. Some research has suggested that the potential life-years gained
from ECIG use may surpass the life-years lost from youth use and subsequent vulnerability to
combustible tobacco use (Warner & Mendez, 2019), while others have suggested that the
popularity of ECIGs among youth could negate any progress made on reducing combustible
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smoking rates (NASEM, 2018). Considering these two competing ideas regarding the influence
of ECIG use on public health, any regulation of ECIGs must keep in mind the different types of
users and their reasons for use. In order to regulate ECIGs comprehensively, a thorough
understanding of device characteristics and how they influence nicotine delivery is imperative.
Protonated nicotine
Nicotine exists in unprotonated (freebase) form or ionized, protonated form. Protonation
can be achieved by altering the pH of nicotine with the addition of an acid (e.g., benzoic acid),
creating a salt. The dissociation constant (pKa) of a molecule allows a prediction to be made
regarding dissociation/ionization based on pH (Hill & Petrucci, 2002). Specifically, dissociation
(i.e., deprotonation) can be predicted based on a pH higher than the pKa, a dissociation constant
(50% deprotonated, 50% protonated) can be predicted based on a pH equal to the pKa, and
ionization (i.e., protonation) can be predicted based on a pH lower than the pKa of a certain
molecule. The pKa of nicotine is 8.02 (Tomar & Henningfield, 1997). Therefore, freebase and
protonated nicotine can be detected in ECIG liquid by measuring pH where a more alkaline pH
>9 indicates mostly freebase nicotine, a more acidic pH <7 indicates mostly protonated nicotine
(El-Hellani et al., 2015; Harvanko et al., 2020b), and a pH ≈8 will be approximately equal parts
freebase and protonated nicotine (Tomar & Henningfield, 1997). Studies have established that
pH modulates nicotine absorption; specifically, increased alkalinity increases nicotine
bioavailability in smokeless tobacco products (Tomar & Henningfield, 1997). When considering
combustible tobacco products, “flue-curing” in the 19th century effectively decreased tobacco pH
compared to the standard “air-cured” tobacco, resulting in decreased harshness upon inhalation
that in part led to the proliferation of combustible cigarettes (Slade, 1989; Milov 2019). In order
to maintain bioavailability of nicotine in combustible cigarettes, blends of air- and flue-cured
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tobacco were engineered to maximize nicotine exposure while simultaneously minimizing
discomfort due to harshness. Tobacco companies also used tobacco plants genetically modified
to have increased nicotine content, compensating for any decreases in nicotine bioavailability
due to protonation, and special protonated nicotine “sprays,” concealing any increases in nicotine
content (Kessler, 1994). In fact, the tobacco industry added levulinic acid to nicotine to create a
salt (protonated nicotine) that was then sprayed on “low-yield” combustible cigarettes,
effectively concealing any harshness that may result from the added nicotine (Kessler, 1994).
Turning to ECIGs, early ECIG liquids contained mostly freebase nicotine, and the
harshness of the aerosol produced by heating these freebase liquids tended to limit their nicotine
content. That is, when ECIG liquids contained nicotine that was majority of the freebase form,
liquid nicotine sold for immediate use in an ECIG (i.e., not for “do-it-yourself” flavor mixing at
home) tended to be no more than 36 mg/ml nicotine. Indeed, when freebase nicotine was
common in ECIG liquids, ECIG-experienced individuals used lower rather than higher
concentration liquids (e.g., Wagener et al., 2017; Harvanko et al., 2018).
However, ECIG liquids evolved to incorporate protonated nicotine in higher
concentrations, mirroring the evolution of combustible cigarettes; a product with a relatively low
nicotine delivery profile has been engineered to deliver more nicotine without any additional
harshness via protonation, albeit at a much swifter pace (Duell et al., 2020). As previously
mentioned, the most popular ECIG in the US is JUUL, a ≈8 W, pod mod device that uses pods
containing 94% protonated nicotine liquid at higher concentrations than typically used when the
nicotine is freebase (>60 mg/ml; Talih et al., 2019). Other available pods and pod mod devices
contain similar concentrations of protonated nicotine (Jackler & Ramamurthi, 2019), and this
type of device accounts for 75% of the ECIG market in the US (Huang et al., 2019).
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Additionally, high concentration protonated nicotine liquid is available in bulk (Jackler &
Ramamurthi, 2019), allowing it to be used in other types of devices including third generation
devices that allow the user to adjust device power.
As discussed previously, protonated nicotine is less aversive at higher concentrations
when compared to freebase nicotine (Henningfield et al., 2004; Pankow, 2001). The increase in
concentration of liquid nicotine available for ECIGs observed since 2015, when JUUL was
introduced, almost certainly is a direct result of the introduction of devices containing protonated
nicotine (Romberg et al., 2019). In a recent study examining the proliferation of high
concentration protonated nicotine liquids, over 100 brands of protonated nicotine liquids >50
mg/ml were identified (Jackler & Ramamurthi, 2019).
The high concentration of protonated nicotine in pod mod devices results in reliable
nicotine delivery even with a considerably lower device power than third generation ECIGs
(Hajek et al., 2020; Maloney et al., 2020; Vargas et al., 2020). Currently, protonated liquid is
available in pods (meant to be used with low powered pod mod devices) and in bulk. The
availability of protonated nicotine liquids in bulk allows this type of liquid to be used in any
device with a refillable reservoir including those with variable voltage (i.e., third generation
devices), and the resulting potential for dramatic increases in nicotine delivery pose a danger to
users. As discussed previously, nicotine emissions increase as much as four times when device
power is increased by a factor of 2.5 (Talih et al., 2015) and studies have demonstrated that
nicotine delivery is increased as device power is increased (Hiler et al., 2020; Wagener et al.,
2017). If experienced users of pod mod devices are able to obtain nicotine delivery comparable
to combustible cigarettes (Hajek et al., 2020; detailed above) with device power <10 W, and
third generation device power can exceed 40 W, the use of high concentration protonated

PHYSIO AND SUBJECTIVE EFFECTS PROTONATED NICOTINE

35

nicotine in third generation devices presents the potential for nicotine delivery that far exceeds
that of a combustible cigarette. This high level of nicotine delivery is especially disturbing when
considering that the majority of ECIG users are youth and young adults (Cullen et al., 2018;
detailed above).
Increased nicotine delivery resulting from the use of protonated nicotine in ECIG devices
could result in increased efficiency when ECIGs are used as combustible cigarette cessation aids.
Though there are few RCTs examining ECIGs in this role, the use of ECIG devices with
increased nicotine delivery could be responsible at least in part for increases in cessation rates at
follow-up (e.g., first versus second generation, as in Bullen et al., 2013 and Hajek et al., 2019).
Existing evidence that the efficacy of NRT is nicotine dose-dependent (Lindson et al., 2019)
suggests that, for any cessation aid used that involves nicotine delivery, greater nicotine delivery
to blood likely will lead to better treatment outcome.
The ability for ECIGs to deliver nicotine also is a concern for public health, and
regulators have begun addressing this concern. For example, in 2014, the European Union (EU)
limited ECIG liquid nicotine concentration to <20 mg/ml in order to ensure that ECIG nicotine
delivery is comparable and not greater than that produced by a combustible cigarette (Kennedy et
al., 2017). Similar ECIG regulations on liquid nicotine concentration have been suggested in the
US (H.R. 4624, 2019), yet little is known about the nicotine delivery of ECIG products
containing protonated nicotine. Existing studies have examined the role of liquid nicotine
concentration in nicotine delivery (e.g., Hiler et al., 2017, detailed above), but these studies used
liquids containing nicotine in freebase form. As indicated previously, the vast majority of
devices used in the US contain protonated nicotine (Huang et al., 2019), and any ECIG
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regulations that involve liquid nicotine concentration should be informed by studies examining
the role of nicotine form on nicotine delivery.
Additionally, any ECIG regulations focused on only liquid nicotine content do not
address the role of device power in determining nicotine delivery (Eissenberg et al., 2020); in
fact, increasing the device power has the potential to negate any decreases to liquid nicotine
concentration, effectively preserving nicotine delivery (as in Hiler et al., 2020; Wagener et al.,
2017). If liquid nicotine concentration is limited in the U.S. to a similar threshold as the EU
regulation, device power has the potential to be used to circumvent the intention of the regulation
and achieve nicotine delivery that exceeds that of a combustible cigarette (Eissenberg et al.,
2020). Alternatively, factors that influence nicotine delivery can be considered together to
determine the rate at which nicotine is emitted from an ECIG (i.e., nicotine flux; Shihadeh &
Eissenberg, 2015). Nicotine flux subsequently may be combined with additional factors (e.g.,
puff duration) to limit effectively the maximum dose of nicotine ECIG users are able to
administer. A thorough understanding of the nicotine delivery profile and subjective effects of
different concentrations of protonated nicotine liquids at different power settings is integral to
creating regulations that are comprehensive; that is, effective regulations that decrease the abuse
liability of ECIGs in order to deter youth initiation without limiting their potential efficacy as
combustible cigarette cessation aids.
Statement of the Problem
The majority of ECIGs currently used in the US contain protonated nicotine liquids at
high concentrations (Huang et al., 2019). The recent increase in ECIG use among youth and
young adults occurred with the introduction of ECIG products containing protonated nicotine
(Romberg et al., 2019). Previous studies have established that the nicotine delivery profile of
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ECIGs is influenced by the concentration of nicotine in the liquid and the power of the device
(Harvanko et al., 2020a; Hiler et al., 2019; Wagener et al., 2017), but these studies have explored
this relationship using freebase nicotine liquids at typical concentrations at the time of study. The
introduction and subsequent rise in popularity of devices containing protonated nicotine in high
concentrations has created an urgent need for further research on the nicotine delivery profile and
subjective effects of protonated liquid at different power and liquid nicotine concentration
combinations.
The Present Study
This study used clinical laboratory methods to examine nicotine delivery and subjective
effects of ECIGs containing protonated nicotine liquids at three concentrations and two device
power settings. Additionally, puff topography was measured to examine how user experience
and behavior may interact to influence nicotine delivery.
Statement of Hypothesis
Previous research has established that as ECIG device power and/or liquid nicotine
concentration increases, nicotine delivery also increases. The hypothesis for this study was that
when protonated nicotine is used at different liquid concentrations and device power settings,
nicotine delivery will approach (or exceed) that observed in previous studies on ECIGs and
combustible cigarettes. In order to understand how device power and liquid concentration
influence nicotine delivery, these parameters must be studied systematically. This study
controlled device power and liquid nicotine concentration to examine the influence of protonated
nicotine containing liquid on nicotine delivery of ECIGs. Additionally, the hypothesis in this
study was that user experience (e.g., harshness, direct effects of nicotine) would result in changes
to puff topography.
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Method
Participant Selection
Participants were recruited via word-of-mouth and Institutional Review Board (IRB)approved community and/or internet advertisements. All screening and experimental sessions
took place at the VCU Center for the Study of Tobacco Products (CSTP). Individuals were
considered eligible for the study if they were healthy, aged 18-55, reported using inhaled tobacco
products and were willing to abstain from tobacco/nicotine as required. Specifically, ECIG users
were required to report use of ECIGs ≥3 months and use of ≥1 ml of liquid per day (or
approximately one cartridge or one pod per day) at a nicotine concentration of ≥3 mg/ml and no
use of tobacco cigarettes in the past 30 days. Cigarette smokers were required to report use of ≥
10 cigarettes per day and no use of an ECIG in the past 30 days. Cigarette smokers were also
required to have an expired air CO concentration at screening of at least 15 ppm and a 'positive'
cotinine cassette result to verify nicotine use. Urine cotinine was measured for all participants at
screening, and a positive test was required to verify nicotine use.
Participants were excluded if they reported a current, diagnosed chronic illness or
psychiatric condition, or psychotropic medication use. Additionally, participants were excluded
if they reported alcohol use >25 days, cannabis use >15 days, or any other illicit drug use
(cocaine, opioids, benzodiazepines, and methamphetamine) in the past 30 days. Biologically
female participants were excluded if they reported currently breast-feeding or if they tested
positive for pregnancy (by urinalysis) at screening. Any participant reporting any intention to
quit tobacco/nicotine use in the next 30 days was excluded and referred to cessation treatment.
Individuals who reported using any other tobacco products (other than what is permitted per the
inclusion criteria) on a weekly or more frequent basis were excluded.
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Informed Consent and Screening
All participants completed a two-part screening process. Interested participants were able
to make initial contact via telephone or website (both provided on advertisements) and answered
questions about their health and current tobacco product use. Based on their answers, eligible
participants were invited to the CSTP to complete an in-person screening visit, where they
provided informed consent to participate in the screening and the study. After consent
procedures, participants completed additional screening questionnaires on demographics, health
status, and tobacco product use. All participants provided a urine sample to test for cotinine and
to test for pregnancy in biologically female participants.
Participant Safety
The methods and procedures used in this study involved minimal risk. Similar methods
and procedures have been used numerous times at the CSTP over the course of 20 years.
Abstinence from nicotine for twelve hours could result in mild discomfort, but this discomfort is
not medically dangerous. Blood drawing procedures involve minimal risk of bruising and/or
infection at the catheter site; these risks were minimized by trained nursing staff and sterile
procedures. Potential risks and/or side effects of using ECIGs were routine for the target
population (users of inhaled tobacco products).
All CSTP staff maintain training on good clinical practices, including the protection of
participants’ safety and rights. Heart rate (HR) and blood pressure (BP) were monitored during
each session. Sessions were ended prematurely if a participant’s HR was below 50 or above 120,
or if a participant’s systolic BP was below 90 or above 140, at any point during the session. Data
were not identified by name or initials; only an alphanumeric code is used as identification. All
data are stored in a locked cabinet available only to CSTP staff.
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Materials
Participants used a third generation ECIG, Kanger Sub Box Mini, set to either 15 watts or
30 watts, which contained either 10 mg/ml, 15 mg/ml, or 30 mg/ml nicotine-containing liquid.
All ECIG devices and liquids were purchased at a local vape shop (AVAIL, Richmond VA).
Liquids were verified independently for liquid nicotine content (within 0.2 mg/ml of labeled
concentration) by VCU’s Bioanalytical Analysis Core Laboratories. All liquids used were 30%
propylene glycol and 70% vegetable glycerin, had a pH of < 7 (this pH indicates a majority of
protonated nicotine, as detailed above), and were available in four flavors (Tobacco, Menthol,
Fruit, Dessert). Participants sampled all flavors during screening and selected their preference for
the duration of the study. Among the 21 participants included in final analyses, flavor choices
were as followed: Tobacco (N=5), Menthol (N=7), Berry (N=8), and Dessert (N=1).
Procedures
After completing informed consent and all screening procedures, participants completed
six sessions at VCU’s CSTP. Each session was approximately 4 hours long and differed by the
combination of wattage and liquid nicotine concentration. Sessions were ordered by Latin-square
and occurred no more than 2 days per week. All sessions were separated by at least 48 hours.
Participants were instructed to abstain from tobacco and nicotine containing products for >12
hours prior to each session. In order to verify overnight abstinence from any combustible tobacco
products, participants’ expired air CO concentration was required to be <10 ppm upon arrival to
the CSTP for each session. Because ECIGs are non-combustible, and CO therefore is not an
indication of ECIG use/abstinence, baseline plasma nicotine concentration was inspected
retrospectively following analysis to identify any non-compliance with overnight abstinence.
Plasma was analyzed after participants complete the study; therefore, a 1-hour waiting period
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was completed before ECIG administration. This waiting period ensured that any participants
who did not comply with overnight abstinence were abstinent for at least one hour before the
session began. After the waiting period, HR and BP monitoring began and an intravenous
catheter was inserted into a forearm vein. A blood sample of 7 ml was drawn, and participants
completed computerized questionnaires reporting any nicotine abstinence symptoms and other
effects (see below). Thirty minutes after the initial HR and BP measurement, participants were
instructed to take 10 puffs of the ECIG; each puff was separated by 30 seconds. A CSTP staff
member instructed the participant when to take each puff and verified compliance. After the
tenth puff, another 7 ml of blood was sampled, and participants completed the same
questionnaires. Participants completed two additional questionnaires following ECIG use: a
computerized questionnaire reporting direct effects of ECIG use and a questionnaire using paper
and pen assessing the flavor, harshness, and throat hit of the ECIG. Twenty minutes after the first
ECIG use period ended, another 7 ml blood sampled was drawn and participants completed the
same computer questionnaires. After completing the questionnaires, participants began an ad
libitum ECIG use period, where they were instructed to use the ECIG as much or as little as they
liked for 90 minutes. Following the ad libitum use period, a final 7 ml blood sample was drawn,
and participants completed the same questionnaires that were completed following the first ECIG
use period. After all questionnaires were completed, the catheter was removed, and the
participant was paid according to the number of sessions they completed thus far. Payment
escalation according to session number was used to encourage study retention. The escalation
schedule was: US $50 for completing the first session, US $75 for completing the second
session, US $100 for completing the third and fourth sessions, US $150 for completing the fifth
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session, and US $175 for completing the sixth session. Thus, the total amount participants earned
for completing the entire study was US $660.
Outcome Measures
Physiological measures. All blood samples were centrifuged and stored at -70°C.
Analysis of plasma nicotine concentration took place at VCU’s Bioanalytical Analysis Core
Laboratories, using a limit of quantitation (LOQ) of 2 ng/ml (as in Maloney et al., 2019).
Participants’ HR was measured via pulse oximeter (Criticare systems) and expired air CO was
measured with a BreathCO monitor (Vitalograph, Lenexa, KS).
Puff topography. Mouthpiece-based puff topography equipment, developed and
manufactured at the American University of Beirut (AUB), was used to measure IPI, flow rate,
puff number, duration, and volume. This equipment is designed specifically to measure the puff
topography of ECIG use and has been used in a number of studies on ECIGs (e.g., Hiler et al.,
2020; Spindle et al., 2018). Specifically, the topography equipment used in this study is designed
to accommodate the slower flow rate associated with ECIG use and has been shown to have no
significant influence on other measures collected in this study (see Spindle et al., 2015). In order
to correct for any measurement error or noise, the topography recording software automatically
corrected for the following: any two puffs separated by <300 ms (combined into one puff) and
any puffs with a duration <300 ms (puff deleted). Mouthpieces were manufactured to fit the
device used in the present study. Prior to each session, the mouthpiece was calibrated using an
automatic digital flow calibrator, also designed and manufactured at AUB. Puff topography was
measured and recorded continuously during each ECIG use period.
Subjective questionnaires. Three questionnaires were administered via computer using
the Visual Analog Scale (VAS) format; for each item, a word or phrase was centered on a
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horizontal line with “not at all” on the left of the line and “extremely” on the right. Participants
clicked on any point of the line with a mouse/cursor and response scores reflected the percentage
of the total line length measured from the left anchor. These questionnaires were administered
before and after the two ECIG use periods, for a total of four times each session. The General
Labeled Magnitude Scale was administered via paper and pen after each ECIG use period, for a
total of two times each session.
Direct Effects of Nicotine. The direct effects and side effects of nicotine were assessed
by the direct effects of nicotine scale, which consists of 11 items: “Confused,” “Dizzy,”
“Headache,” “Heart Pound,” “Lightheaded,” “Nauseous,” “Nervous,” “Salivation,” “Sweaty,”
and “Weak” (Evans et al., 2006; see Appendix A).
Direct Effects of ECIG Use. Adapted from the “Direct Effects of Tobacco” scale
(Breland et al., 2006) to measure the subjective effects of ECIG use, this scale consists of 10
items: “Was the e-cigarette satisfying?,” “Was the e-cigarette pleasant?,” “Did the e- cigarette
taste good?,” “Did the e-cigarette make you dizzy?,” “ Did the e-cigarette calm you down?,”
“Did the e-cigarette help you concentration?,” “Did the e-cigarette make you feel more awake?,”
“Did the e-cigarette reduce your hunger for food?,” “Did the e-cigarette make you sick?,” and
“Would you like another e-cigarette right now?” (see Hiler et al., 2020).
Hughes-Hatsukami Withdrawal Scale. Severity of nicotine withdrawal and severity of
abstinence symptom(s) was assessed by the Hughes-Hatsukami withdrawal scale, which consists
of 11 items: “Anxious,” “Craving and e-cigarette/nicotine,” “Depression,” “ Difficulty
concentrating,” “Drowsy,” “Hunger,” “Impatient,” “Irritable,” “Restlessness,” “Desire for
sweets,” and “Urge to use an ECIG” (Hughes & Hatsukami, 1986).
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General Labeled Magnitude Scale. The General Labeled Magnitude Scale (gLMS) was
used to measure specific sensations associated with ECIG product use. Participants were
instructed to draw a horizontal line indicating their level of sensation, and then write the
corresponding number in a box (see Appendix C). The following ECIG-specific sensations were
measured via paper and pen: “Flavor,” “Harshness,” and “Throat Hit” (Green et al., 1993). This
scale uses a scale of 0-100 and sensation level descriptions at the following numbers: 0 (“No
Sensation at All”, 1 (“Barely Detectable”), 6 (“Weak”), 16 (“Moderate”), 35 (“Strong”), 53
(“Very Strong”), and the highest possible rating of 100 (“Strongest Imaginable Sensation of Any
Kind”).
Participant characteristics.
A total of 84 participants provided informed consent, and 25 of these were determined
ineligible for study participation at the screening visit for failure to meet study criteria (e.g., use
of other tobacco products, besides those specified in study criteria, in the last 30 days). Thirtytwo participants completed at least one session but withdrew or were discontinued before study
completion for the following reasons: failure to follow up (n=11), lack of venous access (n=6),
failure to adhere to study protocol (i.e., unable to remain abstinent for 12 hours prior to each
study session as evidence by expired air CO concentration >10 PPM upon arrival; n=3), and
elevated blood pressure (n=3). Two participants voluntarily withdrew from the study (one for
lack of venous access and one for scheduling conflicts). Additionally, 7 of the 32 participants
who did not complete the study were unable to attend study sessions due to the COVID-19
pandemic. Twenty-seven participants completed all study sessions. Among these 27, five
participants in the ECIG user group were determined (via plasma nicotine concentration) to be
noncompliant (e.g., did not abstain from nicotine and tobacco products for 12 hours prior to at
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least one session) and one participant was unable to give a blood sample during one session.
Thus, a total of 21 participants (13 male, 7 female, 1 other) are included in the final analyses.
No significant differences in age, race, education, or employment were observed between
groups (see Table 1). Collapsed across group, mean age (SD) was 28.8 (8.9) years. Fourteen
participants were Caucasian, 4 were African American, 1 was Asian American, and 2 reported
their race as “other” (“Arab/Middle Eastern” and “Latino”). Thirteen participants reported being
currently employed, 6 reported being unemployed, and 2 reported their employment as
“student.” Mean (SD) expired air CO at screening was 2.5 (0.7) in the ECIG user group and 26.3
(11.5) in the cigarette smoker group.
Among the ECIG user group (n=11), participants reported using a mean (SD) volume of
3.8 ml (3.8) of ECIG liquid daily (mean volume for one participant was not included due to
incomplete information on their preferred device) for a mean (SD) of 15.5 months (12.3). For
reference, a JUUL pod (the most popular ECIG device at the time of this study; Huang et al.,
2019) contains 0.7 ml of nicotine-containing liquid (Talih et al., 2019). The ECIG user group
scored a mean (SD) of 2.2 (0.9) on the E-cigarette Dependence Scale (EDS; Morean et al.,
2019). Flavor choice within the ECIG user group was as followed: Tobacco (n=5), Menthol
(n=3), Berry (n=3), Dessert (n=0).
Among the cigarette smoker group (n=10), participants reported smoking a mean (SD) of
19.2 (8.0) cigarettes per day for 11.7 (7.5) years. The cigarette smoker group scored a mean (SD)
of 5.6 (1.7) on the Fagerström Test of Nicotine Dependence (Heatherton et al., 1991) and a mean
(SD) of 2.1 (0.8) on the Patient Reported Outcomes Measurement Information System
(PROMIS) Short Form v1.0 – Smoking: Nicotine Dependence for All Smokers 4a (Edelen et al.,
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Table 1. Participant demographic information by group and for the entire sample. No significant
differences between groups were observed for any of the characteristics displayed here.
Participant Demographics
Age
Gender
Male

ECIG Users
n=11
24.6 (6.6)

Mean (SD) or N (%)
Cigarette Smokers
n=10
33.3 (9.1)

Entire Sample
N=21
28.8 (8.9)

7 (64%)

6 (60%)

13 (62%)

4 (36%)

3 (30%)

7 (33%)

0

1 (10%)

1 (5%)

Caucasian
African American

8 (73%)
1 (9%)

6 (60%)
3 (30%)

14 (67%)
4 (19%)

Asian American

1 (9%)

0

1 (5%)

Other
Education (years)

1 (9%)
13.5 (1.5)

1 (10%)
12.9 (1.5)

2 (9%)
13.3 (1.5)

7 (64%)

6 (60%)

13 (62%)

3 (27%)

3 (30%)

6 (29%)

1 (9%)

1 (10%)

2 (9%)

Female
Other
Race

Employment
Part or full time employed
Unemployed
Student
Tobacco product use
ECIG users
Volume (ECIG liquid/day in ml)

3.8 (3.8) a

Duration ECIG use (months)

15.5 (12.3)

Cigarette smokers
Cigarettes/day

19.2 (8.0)

Duration cigarette use (years)

11.7 (7.5)

Nicotine dependence
ECIG users
EDS

2.2 (0.9)

Cigarette smokers

a

FTND

5.6 (1.7)

PROMIS

2.1 (0.8)

n = 10
Note: EDS=E-cigarette Dependence Scale; FTND=Fagerström Test for Nicotine Dependence;
PROMIS=Patient Reported Outcomes Measurement Information System Short Form v1.0 –
Smoking: Nicotine Dependence for All Smokers 4a; ECIG=electronic cigarette.
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Data Analysis Plan
A previous CSTP study that manipulated both liquid nicotine concentration and power
(Hiler et al., 2020) was used to estimate effect size for the current study, in order to complete a
priori power analysis and determine adequate sample size. Using data from Hiler et al., 2020,
plasma nicotine partial n2 values for liquid nicotine concentration and device power were
examined separately and the smallest partial n2 for a main effect of device power (0.32) and a
main effect of liquid concentration (0.36) was used to determine effect size (0.69 and 0.75). The
predicted effect sizes were entered into a G*Power repeated measures ANOVA model for an a
priori power calculation (Faul et al., 2007). Results revealed that for plasma nicotine
concentration analysis 10 participants were required to detect a main effect of device power and
nine participants were required to detect a main effect of liquid nicotine concentration (with
power >80% given a Type I error rate of 0.05).
The referenced study did not detect a significant device power by liquid concentration
interaction; the partial n2 (0.15) of a significant device power by time interaction was used to
determine effect size (0.42) and the number of participants needed (17) to detect interaction
effects. The absence of a significant resistance by liquid concentration interaction in the
referenced study could be due to the range of liquid nicotine concentration used (3 mg – 8 mg).
The present study uses a much wider range of liquid nicotine concentration (10 mg – 30 mg); for
this reason, the observed effect size is likely to be larger than that observed in Hiler et al., 2020.
Plasma nicotine concentration values lower than the LOQ (2.0 ng/ml; see Physiological
measures) were replaced with 2.0 ng/ml. This approach is more conservative than replacing each
value below the LOQ with zero and has been used in other studies that measure plasma nicotine
concentration (e.g., Vansickel et al., 2010; Hiler et al., 2020; Maloney et al., 2020). Heart rate

PHYSIO AND SUBJECTIVE EFFECTS PROTONATED NICOTINE

49

data were averaged for 10 minutes before (“baseline”) and throughout each ECIG use period
(three values in total). Data for each topography measure were averaged for each ECIG use
period, with the exception of puff number.
All data analyses were performed with analysis of variance (ANOVA) using IBM SPSS
(Version 27). Specifically, for plasma nicotine concentration and subjective measures that were
administered before and after ECIG use, ANOVAs involved three within-subjects factors: liquid
nicotine concentration (three levels: 10, 15, 30 mg/ml), device power (two levels: 15, 30 W), and
time (four levels: pre-directed, post-directed, pre-ad lib, post-ad lib). For HR, the liquid
concentration and power factors are the same, but the time factor had three levels (baseline,
during directed use, and during ad lib use). For topography and subjective measures
administered after ECIG use (i.e., the direct effects of ECIG use and gLMS), the liquid
concentration and power factors are the same and there was no time factor (i.e., observations
during or after the directed and ad lib use periods were analyzed separately). Additionally,
because the sample involved exclusive cigarette smokers and exclusive ECIG users (see
Participant Characteristics above, and Table 1), there is a potential that ECIG experience may
have influenced each study outcome. Thus, group (two levels: cigarette smokers, ECIG users)
was included as a between-subject factor in all analyses. In cases where no significant main
effect or interactions including the group factor were observed, data were collapsed across group
and reanalyzed using a three factor (for measures involving time as a factor) or two factor (for
measures that did not involve time as a factor; see above) completely within-subjects analysis
(i.e., without the group factor). In order to analyze mean differences across and within factors
(liquid nicotine concentration, device power, and/or time), paired samples t-tests were used.
Bonferroni corrections were used when appropriate (i.e., for non-orthogonal comparisons).
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Results
For outcomes administered pre- and post-ECIG use, the results of particular interest are
those that involve changes from baseline that occurred after ECIG use (either directed or ad lib).
For this reason, the main effect of time and interactions involving the time factor are most
relevant and are described below; where applicable, significant interactions with the betweensubject group factor are also reported. Table 2 displays ANOVA results for the main effect of
Time and all possible interactions that involve the Time factor.
For outcomes not involving time as a factor (i.e., those administered only after ECIG
use), each ECIG use period was analyzed separately and Tables 3, 6, 7, and 8 display these
ANOVA results.
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Table 2. Statistical Analysis Results for Four-Factor Mixed Analysis of Variance (Directed + ad
libitum use periods).
Outcome
Measure

Nicotine* Power*
Time
Time

Time

Nicotine*
Nicotine*
Power*
Power*
Time*
Time
Group
F
ηp2
F
ηp2

F

ηp2

F

ηp2

F

ηp2

F

ηp 2

F

ηp2

26.1 .58

4.6

.20

3.9

.17

3.0

.14

1.6

.08

0.8

.04

1.7

.08

1.1

.05

57.0 .75
F
ηp2
28.5 .60

7.6
F
0.7

.29 11.6 .38
ηp2
F
ηp2
.04 0.4 .02

1.1
F
3.8

.06
ηp2
.17

0.8
F
0.9

.04
ηp 2
.05

0.4
F
0.4

.02
ηp2
.02

1.5
F
2.3

.07
ηp2
.11

1.4
F
0.1

.07
ηp2
.01

Craving

45.4 .71

2.5

.11

2.2

.10

0.5

.03

1.2

.06

0.7

.04

1.5

.07

0.8

.04

Depression
Difficulty
Concentrating

2.9

.13

0.2

.01

0.3

.02

1.1

.05

0.6

.03

0.6

.03

1.5

.07

0.7

.03

13.5 .42

0.8

.04

1.4

.07

0.8

.04

0.4

.02

5.7

.23

1.0

.05

1.0

.05

Drowsy

7.5

.28

2.3

.11

0.5

.02

0.8

.04

3.5

.16

0.6

.03

0.4

.02

1.4

.07

Hunger

5.7

.23

2.4

.11

3.1

.14

0.1

.01

1.1

.06

2.4

.11

2.5

.12

1.9

.09

Impatient

13.4 .41

1.6

.08

0.4

.02

1.7

.08

1.0

.05

0.4

.02

2.0

.09

0.5

.02

Irritable

32.4 .63

0.5

.02

1.0

.05

4.8

.20

0.9

.05

0.0

.00

1.6

.08

0.4

.02

Restless

8.9

.32

0.9

.05

0.5

.03

0.6

.03

0.6

.03

1.8

.09

0.6

.03

1.1

.06

Sweets

2.7

.13

1.3

.06

0.3

.01

1.6

.08

1.4

.07

1.6

.08

0.3

.02

1.4

.07

Urge
DE Nicotine a
Confused

54.3 .74
F
ηp2
2.4 .11

1.2
F
0.1

.06
ηp2
.01

0.5
F
0.3

.03
ηp2
.02

0.3
F
0.2

.02
ηp2
.01

1.1
F
1.1

.05
ηp 2
.05

0.9
F
3.5

.05
ηp2
.16

0.7
F
0.9

.03
ηp2
.05

0.5
F
1.0

.03
ηp2
.05

Dizzy

7.2

.28

1.5

.07

5.3

.22

0.0

.00

0.3

.02

1.6

.08

0.5

.03

0.5

.02

Headache

1.6

.08

0.6

.03

0.6

.03

0.3

.02

0.9

.05

1.8

.09

1.1

.06

1.4

.07

Heart Pounding 4.9

.21

0.7

.04

3.8

.17

1.3

.07

2.8

.13

1.2

.06

1.0

.05

3.5

.16

Lightheaded

11.9 .39

1.6

.08

4.3

.19

1.0

.05

1.9

.09

4.4

.19

1.0

.05

0.8

.04

Nauseous

2.6

.12

1.5

.08

4.5

.19

2.9

.13

0.7

.04

1.3

.06

0.8

.04

2.0

.09

Nervous

4.7

.20

0.4

.02

0.9

.05

0.6

.03

0.7

.04

1.8

.09

0.6

.03

0.5

.03

Salivation

0.5

.02

0.9

.04

0.1

.01

0.7

.03

0.5

.03

0.9

.05

0.3

.01

1.8

.09

Sweaty

0.7

.03

0.7

.04

0.2

.01

0.5

.03

0.5

.03

1.0

.05

1.6

.08

0.8

.04

Weak

2.6

.12

0.9

.05

1.2

.06

0.3

.01

2.1

.10

0.4

.02

2.5

.12

0.9

.05

F
Plasma
Nicotine a
HR b
HH a
Anxious

a

ηp2

Nicotine* Power*
Time*
Time*
Group
Group

Time*
Group

df T=(3,57); df N*T=(6,114); df P*T=(3,57); df T*G=(3,57); df N*T*G=(6,114); df
P*T*G=(3,57); df N*P*T=(6,114); df N*P*T*G=(6,114)
b df T=(2,38); df N*T=(4,76); df P*T=(2,38); df T*G=(2,38); df N*T*G=(4,76); df
P*T*G=(2,38); df N*P*T=(4,76); df N*P*T*G=(4,76)
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Physiological Measures
Plasma Nicotine Concentration
As displayed in Table 2, no statistically significant interactions including the group factor
(cigarette smokers, ECIG users) were observed, therefore plasma nicotine data were re-analyzed
using a three factor completely within-subject ANOVA (i.e., with no group factor) and those
results are reported here.
Significant interactions were observed for liquid nicotine concentration by time
[F(6,120)=4.7, p<0.05] and device power by time [F(3,60)=3.9, p<0.05]. The means (± 1 SEM)
for all conditions across time are depicted in Figure 2 Panels A (15 W) and B (30 W). As the
figure shows, pre-directed use period plasma nicotine concentration means in all conditions were
low and did not differ significantly by condition. However, mean plasma nicotine concentration
increased significantly over time for each liquid nicotine concentration level (i.e., 10, 15, 30
mg/ml) at each power setting (i.e., 15, 30 W) after the directed use period, [ts(20)>5.4, ps<0.05].
For example, at 15 W for the 10 mg/ml condition, pre-directed mean plasma nicotine
concentration was 2.1 ng/ml (SEM=0.1) and increased to 11.2 (SEM=1.7; p<0.05); at 15 W for
the 15 mg/ml condition, mean plasma nicotine concentration was 2.1 (SEM=0.1) and increased
to 8.9 (SEM=1.3; p<0.05); at 15 W for the 30 mg/ml condition, mean plasma nicotine
concentration was 2.1 (SEM=0.1) and increased to 16.1 (SEM=2.8; p<0.05; See Figure 2, Panel
A). Similarly, at 30 W for the 10 mg/ml condition, pre-directed mean plasma nicotine
concentration was 2.2 (SEM=0.1) and increased to 13.9 (SEM=2.1; p<0.05); at 30 W for the 15
mg/ml condition, mean plasma nicotine concentration was 2.0 (SEM=0.02) and increased to 15.2
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(2.8; p<0.05); at 30 W for the 30 mg/ml condition, mean plasma nicotine concentration was 2.2
(SEM=0.1) and increased to 21.4 (SEM=4.2; p<0.05; See Figure 2, Panel B).
Mean plasma nicotine concentration was significantly greater in the 15 mg/ml liquid
nicotine condition at 30 W (M=15.2, SEM=2.8) when compared to 15 W [(M=8.9, SEM=1.3);
t(20)=-3.4, p<.05] after the directed use period. No significant differences were observed across
liquid nicotine concentration [ps>0.025] following the directed use period.
Following the ad lib use period, mean plasma nicotine concentration increased
significantly over time for each liquid nicotine concentration level at each power setting
[ts(20)>5.1, ps<0.05]. For example, at 15 W for the 10 mg/ml condition, pre-ad lib use period
mean plasma nicotine concentration was 4.5 (SEM=0.5) and increased significantly to 16.7
(SEM=2.7; p<.05); at 15 W for the 15 mg/ml condition, mean plasma nicotine concentration was
4.6 (SEM=0.5) and increased to 15.4 (SEM=3.3; p<0.05); at 15 W for the 30 mg/ml condition,
mean plasma nicotine concentration was 5.9 (SEM=0.7) and increased to 19.4 (SEM=3.3;
p<0.05; See Figure 2, Panel A). Similarly, at 30 W for the 10 mg/ml condition, mean plasma
nicotine concentration was 6.6 (SEM=1.0) and increased to 17.4 (SEM=3.0; p<0.05); at 30 W for
the 15 mg/ml condition, mean plasma nicotine concentration was 7.1 (SEM=0.8) and increased
to 20.4 (SEM=3.7; p<0.05); at 30 W for the 30 mg/ml condition, mean plasma nicotine
concentration was 9.0 (SEM=1.0) and increased to 16.2 (SEM=2.8; p<0.05; See Figure 2, Panel
B).
No significant differences were observed after the ad lib use period across liquid nicotine
concentration [ps>0.025] or device power setting [ps>0.05].
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Figure 2. Mean data (± SEM) for plasma nicotine across conditions (N=21).
Participants completed a directed, 10-puff use period and a 90-minute ad libitum use period (use
periods shaded gray) in six conditions based on liquid nicotine concentration condition (10
mg/ml, circle symbol; 15 mg/ml, square symbol; 30 mg/ml, triangle symbol) and device power
setting (15 W, Panel A; 30 W Panel B). Filled symbols indicate a significant difference from prebout plasma nicotine concentration (same condition). Number sign (#) indicates significant
difference from 10 mg at same time point (none observed in the current figure). Asterisk (*)
indicates significant difference from 15 W at same time point. Carat (^) indicates significant
difference from ECIG users at same condition and timepoint (none observed in the current
figure). All p’s <0.05; paired samples t-tests.
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Heart Rate
For heart rate (HR), significant interactions were observed for liquid nicotine
concentration by time and device power by time; no significant main effect of group or
significant interactions involving the group factor were observed. Therefore, HR data was reanalyzed using a three factor completely within-subject ANOVA (i.e., with no group factor), and
those results are reported here.
Significant interactions were observed for liquid nicotine concentration by time
[F(4,80)=7.7, p<0.05] and device power by time [F(2,40)=12.1, p<0.05]. The means (± 1 SEM)
for all conditions across time are depicted in Figure 3 Panels A (15 W) and B (30 W). Similar to
plasma nicotine concentration, HR increased significantly over time for each liquid nicotine
concentration level (i.e., 10, 15, 30 mg/ml) at each power setting (i.e., 15, 30 W) during the
directed use period, [ts(20)<-6.4, ps<0.05]. For example, at 15 W for the 10 mg/ml condition,
baseline mean HR was 65.5 BPM (SEM=1.4) and increased to 76.6 (SEM=2.1; p<0.05); at 15 W
for the 15 mg/ml condition, baseline mean HR was 64.7 BPM (SEM=2.1) and increased to 75.9
(SEM=3.0; p<0.05); at 15 W for the 30 mg/ml condition, baseline mean HR was 64.8 BPM
(SEM=1.8) and increased to 78.4 (SEM=2.6; p<0.05). Similarly, at 30 W for the 10 mg/ml
condition, baseline mean HR was 65.8 BPM (SEM=1.9) and increased to 78.9 (SEM=2.8;
p<0.05); at 30 W for the 15 mg/ml condition, baseline mean HR was 64.5 BPM (SEM=2.0) and
increased to 78.4 (SEM=2.5; p<0.05); at 30 W for the 30 mg/ml condition, baseline mean HR
was 64.0 (SEM=1.9) and increased to 83.3 (SEM=3.0; p<0.05).
Also, significant differences across liquid nicotine concentration and device power
setting were observed during the directed use period. Specifically, mean HR was greater in the
30 mg/ml;30 W condition (M=83.3, SEM=3.0) when compared to the 10 mg/ml;30 W condition
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[(M=78.9, SEM=2.8); t(20)=-2.7, p<0.025]. Additionally, mean HR was significantly different
when comparing the 30 mg/ml liquid nicotine condition at 15 W (M=78.4, SEM=2.6) and 30 W
[(M=83.3, SEM=3.0); t(20)=-2.5, p<0.05].
During the ad lib use period, mean HR increased significantly over time for each liquid
nicotine concentration level at each power setting [ts(20)<-4.1, ps<0.025]. For example, at 15 W
for the 10 mg/ml condition, baseline mean HR was 65.5 BPM (SEM=1.4) and increased
significantly to 73.4 (SEM=2.3; p<0.025); at 15 W for the 15 mg/ml condition, mean HR was
64.7 BPM (SEM=2.1) and increased to 72.0 (SEM=2.7; p<0.025); at 15 W for the 30 mg/ml
condition, mean HR was 64.8 BPM (SEM=1.8) and increased to 73.0 (SEM=2.2; p<0.025; See
Figure 3, Panel A). Similarly, at 30 W for the 10 mg/ml condition, baseline mean HR was 65.8
BPM (SEM=1.9) and increased to 73.8 BPM (SEM=2.6; p<0.025); at 30 W for the 15 mg/ml
condition, mean HR was 64.5 BPM (SEM=2.0) and increased to 74.0 (SEM=2.1; p<0.025); at 30
W for the 30 mg/ml condition, mean HR was 64.0 (SEM=1.9) and increased to 72.6 (SEM=2.4;
p<0.025; See Figure 3, Panel B).
No significant differences were observed during the ad lib use period across liquid
nicotine conditions [ps>0.025] or device power settings [ps>0.05].
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Figure 3. Mean data (± SEM) for HR across conditions (N=21).
In all other respects, the figure is identical to Figure 2.
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Puff Topography
Topography observations occurred during ECIG use only. Therefore, the factor of time
was not included in analysis and the directed and ad lib use periods were analyzed separately.
The liquid concentration, power, and group factors are the same as all other measures. As
displayed in Table 3, statistically significant interactions including the group factor were
observed in items Puff Count, Duration, and Volume during the ad lib period only. No
significant interactions including the group factor were observed during the directed use period
for any topography items, nor during the ad lib use period for IPI and AFR. Therefore, the
directed use period for all items, as well as IPI and AFR (both use periods) were re-analyzed
using a two factor completely within-subject ANOVA (i.e., with no group factor), and these
results are reported here. Significant group interactions are reported when appropriate. The
means (SEM) for all conditions in each topography measure are displayed in Table 4. Group
differences in puff count, puff volume, and puff duration during the ad lib use period are
displayed in Table 5.
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Table 3. Statistical Analysis Results for Three-Factor Mixed Analysis of Variance (Directed + ad
libitum use periods).
Nicotine

Topography
Puff Count
Directed a
Ad libitum b
Puff Duration a
Directed
Ad libitum
Puff Volume
Directed a
Ad libitum b
IPI
Directed a
Ad libitum b
AFR
Directed a
Ad libitum b

Power

Nicotine *
Power

Nicotine *
Group

Power *
Group

Nicotine *
Power *
Group
F
ηp2

F

ηp2

F

ηp2

F

ηp2

F

ηp2

F

ηp2

2.5
3.5

.13
.18

4.6
2.3

.21
.13

1.2
0.3

.06
.02

0.3
1.0

.02
.06

2.4
4.8

.12
.23

2.3
0.9

.12
.05

22.7
9.8

.57
.38

85.6
76.9

.83
.83

2.3
4.1

.12
.21

1.9
2.3

.10
.12

1.2
4.9

.07
.23

1.3
2.8

.07
.15

9.9
5.6

.37
.26

38.4
35.4

.69
.69

2.6
1.3

.13
.07

1.0
0.5

.06
.03

1.2
6.1

.07
.28

0.3
0.6

.02
.04

2.5
6.5

.13
.29

19.7
3.2

.54
.17

1.1
3.6

.06
.18

0.1
1.7

.00
.09

0.2
0.9

.01
.06

2.2
2.2

.12
.12

0.1
1.0

.01
.06

2.7
2.1

.14
.12

0.3
0.1

.02
.01

0.0
0.0

.00
.00

1.4
0.5

.08
.03

0.0
0.2

.00
.02

a

df N=(2,34); df P=(1,17); df N*P=(2,34); df N*G=(2,34); df P*G=(1,17); df N*P*G=(2,34)

b

df N=(2,32); df P=(1,16); df N*P=(2,32); df N*G=(2,32); df P*G=(1,16); df N*P*G=(2,32)
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Table 4. Mean (SEM) Puff Topography by Liquid Nicotine Concentration and Device Power
(Directed + ad libitum use periods).
10 mg
15 W
Puff count
Directed a
Ad libitum b
Puff duration (sec)
Directed a
Ad libitum b
Puff volume (ml)
Directed a
Ad libitum b
Inter-puff Interval
Directed a
Ad libitum b
Flow rate (ml/sec)
Directed a
Ad libitum b

15 mg

30 mg

30 W

15 W

30 W

15 W

30 W

10.1 (.1)
50.1 (12.9)

9.9 (.1)
44.1 (8.3)

10.5 (.3)
44.7 (5.6)

10.1 (.1)
38.5 (7.2)

10.0 (.1)
35.4 (7.2)

9.9 (.1)
34.6 (11.0)

3.73 (.30)
3.81 (.41)

2.50 (.19)*
2.20 (.21)

3.21 (.22)#
3.28 (.30)

2.12 (.14)*#
1.93 (.16)

2.87 (.19)#
2.99 (.24)

2.04 (.19)*#
1.93 (.22)

667.8 (94.4) 410.5 (57.2)*
600.0 (103.0) 326.9 (58.5)

537.0 (68.3)#
536.1 (93.0)

346.2 (47.2)*# 464.5 (56.8)#
298.5 (54.3)
459.4 (75.4)

316.0 (47.9)*#
267.1 (45.8)

25.8 (.3)
184.7 (47.3)

27.5 (.3)*
130.3 (11.8)

26.1 (.7)
126.8 (13.2)

27.9 (.4)
171.9 (24.0)#

27.1 (.4)#
187.0 (23.6)

27.8 (.3)
298.0 (65.0)*#

172.6 (16.7)
160.5 (21.0)

156.0 (14.7)
145.4 (15.7)

162.7 (14.7)
149.9 (16.0)

156.2 (16.0)
140.8 (16.9)

172.1 (24.6)
146.1 (16.1)

149.4 (16.0)
129.3 (15.0)

a

n=19
n=18
Note: Asterisk (*) indicates significant difference from 15 W at same time point. Number sign
(#) indicates significant difference from 10 mg at same time point.
b

Table 5. Mean (SEM) Puff Topography by Group, Liquid Nicotine Concentration, and Device
Power (ad libitum use period).
10 mg

15 mg

15 W

30 W

Count
ECIG users c
Smokers c

44.0 (9.1)
56.1 (24.8)

37.7 (6.1)
50.4 (15.6)

Duration (sec)
ECIG users c
Smokers c

4.85 (.49)
2.78 (.46)^

Volume (ml)
ECIG users c
Smokers c

836.7 (157.5)
363.4 (79.4)^

c

15 W

30 mg
30 W

15 W

30 W

45.7 (8.3)
43.7 (8.0)

31.6 (5.8)*
45.4 (13.2)

31.2 (4.6)
39.6 (14.0)

20.0 (5.4)*#
49.1 (20.9)

2.70 (.28)*
1.71 (.21)^*

4.04 (.36)#
2.53 (.34)^

2.30 (.20)*#
1.55 (.18)^*

3.53 (.28)#
2.44 (.30)^

2.39 (.35)*
1.47 (.15)^*

438.8 (94.8)*
215.1 (49.4)^*

753.0 (147.7)
319.3 (56.5)^

419.4 (85.1)*
640.3 (104.5)
177.6 (40.4)^*# 278.4 (71.0)^

377.3 (70.9)*
156.9 (29.1)^

n=9
Note: Carat (^) indicates significant difference from ECIG user group within the same condition.
Asterisk (*) indicates significant difference from 15 W within the same group and liquid nicotine
concentration condition. Number sign (#) indicates significant difference from 10 mg within the
same group and device power setting.
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Puff Count. A significant main effect of power was observed during the directed use
period (see Table 3); no significant main effect of group or significant interactions involving the
group factor were observed for puff count during the directed use period. Therefore, puff count
during the directed use period was re-analyzed using a two factor completely within-subject
ANOVA (i.e., with no group factor), and no main effects or interactions were observed. During
the ad lib use period, a significant interaction was observed for power by group (see Table 3).
The means for puff count in all conditions collapsed across group are displayed in Table 4. As
displayed in the table, puff count did not differ during the directed use period, as expected. The
means for puff count by group and condition during the ad lib use period are displayed in Table
5. As displayed in the table, puff count decreased as liquid nicotine concentration and device
power setting increased during the ad lib use period.
Significant differences in puff count during the ad lib use period were revealed in the
ECIG user group only (see Table 5). Specifically, in the 30 W condition, mean puff count was
significantly greater in the 10 mg/ml condition (M=37.7, SEM=6.1) when compared to the 30
mg/ml condition [(M=20.0, SEM=5.4); t(8)=5.6, p<0.025]. In the 15 mg/ml condition, mean puff
count was significantly greater in the 15 W condition (M=45.7, SEM=8.3) when compared to the
30 W condition [(M=31.6, SEM=5.8); t(8)=2.7, p<0.05]. Additionally, in the 30 mg/ml
condition, mean puff count was significantly greater in the 15 W condition (M=31.2, SEM=4.6)
when compared to the 30 W condition [(M=20.0, SEM=5.4); t(8)=5.0, p<0.05] during the ad lib
use period (see Table 5).
No significant differences in puff count were observed across liquid nicotine
concentration [ps>0.025] or device power setting [ps>0.05] during the directed or ad lib use
periods in the cigarette smoker group.
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Puff Duration. Significant main effects of device power and liquid nicotine
concentration were observed for puff duration during the directed use period (see Table 3); no
significant main effect of group or significant interactions involving the group factor were
observed for puff duration during the directed use period. Therefore, puff duration during the
directed use period was re-analyzed using a two factor completely within-subject ANOVA (i.e.,
with no group factor), and significant main effects of device power [F(1,18)=85.8, p<0.05] and
liquid nicotine concentration [F(2,36)=22.3, p<0.05] were observed. During the ad lib use
period, a significant interaction was observed for power by group, as well as a significant
interaction for nicotine by power (see Table 3). Additionally, main effects of device power and
liquid nicotine concentration were observed during the ad lib use period (see Table 3). The
means for puff duration in all conditions collapsed across group are displayed in Table 4. As the
table shows, puff duration decreased as liquid nicotine concentration and device power setting
increased. The means for puff duration by group and condition during the ad lib use period are
displayed in Table 5.
Significant differences in puff duration across power setting and liquid nicotine
concentration were observed during the directed use period. Specifically, in the 10 mg/ml
condition, mean puff duration was significantly greater in the 15 W condition (M=3.7, SEM=0.3)
when compared to the 30 W condition [(M=2.5, SEM=0.2); t(18)=6.8, p<0.05]. Similarly, within
the 15 mg/ml condition, mean puff duration was significantly greater in the 15 W condition
(M=3.2, SEM=0.2) when compared to the 30 W condition [(M=2.1, SEM=0.1); t(18)=8.2,
p<0.05]; within the 30 mg/ml condition, mean puff duration was significantly greater in the 15
W condition (M=2.9, SEM=0.2) when compared to the 30 W condition [(M=2.0, SEM=0.2);
t(18)=5.6, p<0.05]. Comparing across liquid nicotine concentration conditions, within the 15 W
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condition, mean puff duration was significantly greater in the 10 mg/ml condition (M=3.7,
SEM=0.3) when compared to the 15 mg/ml condition [(M=3.2, SEM=0.2); t(18)=3.0, p<0.025],
and when compared to the 30 mg/ml condition [(M=2.9, SEM=0.2); t(18)=4.5, p<0.025].
Similarly, within the 30 W condition, mean puff duration was significantly greater in the 10
mg/ml condition (M=2.5, SEM=0.2) when compared to the 15 mg/ml condition [(M=2.1,
SEM=0.1); t(18)=3.6, p<0.025], as well as to the 30 mg/ml condition [(M=2.0, SEM=0.2);
t(18)=5.0, p<0.025].
During the ad lib use period, significant differences were observed between groups in all
conditions [ts(16)>2.2, p<0.05]. Within the ECIG user group, significant differences between
power setting and liquid nicotine concentration conditions were observed during the ad lib use
period (see Table 5). Specifically, in the 10 mg/ml condition, mean puff duration was
significantly greater in the 15 W condition (M=4.9, SEM=0.5) when compared to the 30 W
condition [(M=2,7, SEM=0.3); t(8)=6.6, p<0.05]. Similarly, within the 15 mg/ml condition,
mean puff duration was significantly greater in the 15 W condition (M=4.0, SEM=0.4) when
compared to the 30 W condition [(M=2.3, SEM=0.2); t(8)=6.6, p<0.05]; within the 30 mg/ml
condition, mean puff duration was significantly greater in the 15 W condition (M=3.5, SEM=0.3)
when compared to the 30 W condition [(M=2.4, SEM=0.6); t(8)=4.4, p<0.05]. Comparing across
liquid nicotine concentration conditions, within the 15 W condition, mean puff duration was
significantly greater in the 10 mg/ml condition (M=4.9, SEM=0.5) when compared to the 15
mg/ml condition [(M=4.0, SEM=0.4); t(8)=3.1, p<0.025], and when compared to the 30 mg/ml
condition [(M=3.5, SEM=0.3); t(8)=4.7, p<0.025]. Similarly, within the 30 W condition, mean
puff duration was significantly greater in the 10 mg/ml condition (M=2.7, SEM=0.3) when
compared to the 15 mg/ml condition [(M=2.3, SEM=0.2); t(8)=3.1, p<0.025].
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Within the cigarette smoker group, significant differences across power setting conditions
were observed during the ad lib use period (see Table 5). Specifically, in the 10 mg/ml condition,
mean puff duration was significantly greater in the 15 W condition (M=2.8, SEM=0.5) when
compared to the 30 W condition [(M=1.7, SEM=0.2); t(8)=3.4, p<0.05]. Similarly, within the 15
mg/ml condition, mean puff duration was significantly greater in the 15 W condition (M=2.5,
SEM=0.3) when compared to the 30 W condition [(M=1.6, SEM=0.2); t(8)=4.8, p<0.05]; within
the 30 mg/ml condition, mean puff duration was significantly greater in the 15 W condition
(M=2.4, SEM=0.3) when compared to the 30 W condition [(M=1.5, SEM=0.2); t(8)=4.4,
p<0.05].
Puff Volume. Significant main effects of device power and liquid nicotine concentration
were observed for puff volume during the directed use period (see Table 3); no significant main
effect of group or significant interactions involving the group factor were observed for puff
volume during the directed use period. Therefore, puff volume during the directed use period
was re-analyzed using a two factor completely within-subject ANOVA (i.e., with no group
factor), and significant main effects of device power [F(1,18)=38.8, p<0.05] and liquid nicotine
concentration [F(2,36)=10.3, p<0.05] were observed. During the ad lib use period, a significant
interaction was observed for power by group, as well as main effects of device power and liquid
nicotine concentration (see Table 3). The means for puff volume in all conditions collapsed
across group are displayed in Table 4. As the table shows, puff volume decreased as liquid
nicotine concentration and device power setting increased. The means for puff volume by group
and condition during the ad lib use period are displayed in Table 5.
Significant differences across power setting and liquid nicotine concentration conditions
were observed during the directed use period. Specifically, in the 10 mg/ml condition, mean puff
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volume was significantly greater in the 15 W condition (M=667.8, SEM=94.4) when compared
to the 30 W condition [(M=410.5, SEM=57.2); t(18)=5.0, p<0.05]. Similarly, within the 15
mg/ml condition, mean puff volume was significantly greater in the 15 W condition (M=537.0,
SEM=68.3) when compared to the 30 W condition [(M=346.2, SEM=47.2); t(18)=5.8, p<0.05];
within the 30 mg/ml condition, mean puff volume was significantly greater in the 15 W
condition (M=464.5, SEM=56.8) when compared to the 30 W condition [(M=316.0, SEM=47.9);
t(18)=3.9, p<0.05]. Comparing across liquid nicotine concentration conditions, within the 15 W
condition, mean puff volume was significantly greater in the 10 mg/ml condition (M=667.8,
SEM=94.4) when compared to the 15 mg/ml condition [(M=537.0, SEM=68.3); t(18)=2.9,
p<0.025], and when compared to the 30 mg/ml condition [(M=464.5, SEM=56.8); t(18)=3.1,
p<0.025]. Additionally, within the 30 W condition, mean puff volume was significantly greater
in the 10 mg/ml condition (M=410.5, SEM=57.2) when compared to the 15 mg/ml condition
[(M=346.2, SEM=47.2); t(18)=2.8, p<0.025], as well as to the 30 mg/ml condition [(M=316.0,
SEM=47.9); t(18)=4.0, p<0.025].
During the ad lib use period, independent samples t-tests revealed significant differences
between groups in all conditions [ts(16)>2.0, p<0.05]. Within the ECIG user group, significant
differences between power setting condition were observed during the ad lib use period (see
Table 5). Specifically, in the 10 mg/ml condition, mean puff volume was significantly greater in
the 15 W condition (M=836.7, SEM=157.5) when compared to the 30 W condition [(M=438.8,
SEM=94.8); t(8)=3.9, p<0.05]. Similarly, within the 15 mg/ml condition, mean puff volume was
significantly greater in the 15 W condition (M=753.0, SEM=147.7) when compared to the 30 W
condition [(M=419.4, SEM=85.1); t(8)=4.3, p<0.05]; within the 30 mg/ml condition, mean puff
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volume was significantly greater in the 15 W condition (M=640.3, SEM=104.5) when compared
to the 30 W condition [(M=377.3, SEM=70.9); t(8)=4.7, p<0.05].
Within the cigarette smoker group, significant differences across power setting and liquid
nicotine concentration conditions were observed during the ad lib use period (see Table 5).
Specifically, in the 10 mg/ml condition, mean puff volume was significantly greater in the 15 W
condition (M=363.4, SEM=79.4) when compared to the 30 W condition [(M=215.1, SEM=49.4);
t(8)=2.3, p<0.05]. Similarly, within the 15 mg/ml condition, mean puff volume was significantly
greater in the 15 W condition (M=319.3, SEM=56.5) when compared to the 30 W condition
[(M=177.6, SEM=40.4); t(8)=3.7, p<0.05]. Comparing across liquid nicotine concentration
conditions, within the 30 W condition, mean puff volume was significantly greater in the 10
mg/ml condition (M=215.1, SEM=49.4) when compared to the 15 mg/ml condition [(M=177.6,
SEM=40.4); t(8)=3.0, p<0.025].
Inter-puff Interval (IPI). A significant main effect of device power was observed for IPI
during the directed use period (see Table 3); no significant main effect of group or significant
interactions involving the group factor were observed for IPI during the directed use period.
Therefore, IPI during the directed use period was re-analyzed using a two factor completely
within-subject ANOVA (i.e., with no group factor), and a significant main effect of device power
[F(1,18)=20.4, p<0.05] was observed. During the ad lib use period, a significant main effect of
liquid nicotine concentration was observed (see Table 3); as in the directed use period, no
significant main effect of group or significant interactions involving the group factor were
observed for IPI during the ad lib use period. Therefore, IPI during the ad lib use period was reanalyzed using a two factor completely within-subject ANOVA (i.e., with no group factor), and a
significant main effect of liquid nicotine concentration [F(2,34)=6.2, p<0.05] was observed. The
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means for IPI in all conditions collapsed across group are displayed in Table 4. As the table
shows, IPI decreased as liquid nicotine concentration and device power setting increased.
Significant differences across power setting and liquid nicotine concentration conditions
were observed during the directed use period. Specifically, in the 10 mg/ml condition, mean IPI
was significantly greater in the 15 W condition (M=25.8, SEM=0.3) when compared to the 30 W
condition [(M=27.5, SEM=0.3); t(18)=-6.0, p<0.05]. Comparing across liquid nicotine
concentration conditions, within the 15 W condition, mean IPI was significantly greater in the 10
mg/ml condition (M=25.8, SEM=0.3) when compared to the 30 mg/ml condition [(M=27.1,
SEM=0.4); t(18)=-2.9, p<0.025].
During the ad lib use period, a significant difference across liquid nicotine concentration
conditions was observed. Specifically, in the 30 W condition, mean IPI was significantly greater
in the 10 mg/ml condition (M=130.3, SEM=11.8) when compared to the 30 mg/ml condition
[(M=298.0, SEM=65.0); t(17)=-2.7, p<0.025].
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Subjective Effects
Hughes-Hatsukami
Statistically significant interactions including the group factor were observed in the
following items: Anxious, Difficulty Concentrating, Drowsy, and Irritable (see Table 2), and
these items were analyzed using a four factor mixed (within and between subjects) ANOVA. For
the remaining HH items, no significant interactions including the group factor were observed.
Therefore, all remaining items were re-analyzed using a three factor completely within-subject
ANOVA (i.e., with no group factor). Significant main effects of group and significant
interactions including the group factor are detailed below.
Anxious. For the item “anxious”, a significant interaction was observed for time by
group (see Table 2). The means (± 1 SEM) for both groups across time are depicted in Figure 4
Panels A (directed use period) and B (ad lib use period). As the figure shows, mean anxious
ratings appeared to differ by group prior to the directed use period, though independent samples
t-tests did not reveal a significant difference between groups at any time point [ps>0.05].
Significant differences were revealed when comparing anxious ratings pre- and postdirected use period within each group. In the ECIG user group, pre-directed mean anxious
ratings were 24.8 (SEM=6.7) and significantly decreased to 13.6 [(SEM=3.8); t(10)=2.7,
p<0.05]. Additionally, in the cigarette smoker group, pre-directed mean anxious ratings were
39.4 (SEM=7.9) and significantly decreased to 10.8 [(SEM=3.7); t(9)=4.4, p<0.05].
A significant difference was observed within the cigarette smoker group when comparing
mean anxious ratings pre- and post-ad lib use period. Specifically, pre-ad lib mean anxious
ratings were 11.5 (SEM=4.2) and significantly decreased to 8.1 [(SEM=3.2); t(9)=2.8, p<0.05].
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Significant differences were not observed when comparing across liquid nicotine
conditions [ps>0.025], or device power settings [ps>0.05] following the ad lib use period.
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Figure 4. Mean data (± SEM) for the Hughes-Hatsukami “Anxious” item by group, collapsed
across liquid nicotine concentration and device power setting (N=21).
ECIG users (n=11; diamond symbol) and cigarette smokers (n=10; hexagon symbol) completed
a directed, 10-puff use period and a 90-minute ad libitum use period. In all other respects, the
figure is identical to Figure 2.
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Craving. For the item “craving an e-cigarette/cigarette/nicotine”, a significant interaction
was observed for liquid nicotine concentration by time (see Table 2); no significant main effect
of group or significant interactions involving the group factor were observed. Therefore,
“craving an e-cigarette/cigarette/nicotine” was re-analyzed using a three factor completely
within-subject ANOVA (i.e., with no group factor), and a significant interaction was observed
for liquid nicotine concentration by time [F(6,120)=2.5, p<0.05]. The means (± 1 SEM) for all
conditions across time are depicted in Figure 5 Panels A (15 W) and B (30 W). As the figure
shows, mean craving ratings did not differ significantly by condition prior to the directed use
period. However, craving ratings decreased significantly over time for each liquid nicotine
concentration level (i.e., 10, 15, 30 mg/ml) at each power setting (i.e., 15, 30 W) after the
directed use period, [ts(20)>4.4, ps<0.05]. For example, at 15 W for the 10 mg/ml condition, predirected mean craving ratings were 80.7 (SEM=5.6) and significantly decreased to 55.0
(SEM=7.0; p<0.05); at 15 W for the 15 mg/ml condition, mean craving ratings were 79.8
(SEM=6.1) and significantly decreased to 41.0 (SEM=7.7; p<0.05); at 15 W for the 30 mg/ml
condition, mean craving ratings were 73.8 (SEM=7.3) and significantly decreased to 41.1
(SEM=6.3; p<0.05). Similarly, at 30 W for the 10 mg/ml condition, pre-directed mean craving
ratings were 72.4 (SEM=7.1) and significantly decreased to 41.5 (SEM=6.0; p<0.05); at 30 W
for the 15 mg/ml condition, mean craving ratings were 70.4 (SEM=7.4) and significantly
decreased to 34.3 (SEM=6.0; p<0.05); at 30 W for the 30 mg/ml condition, mean craving ratings
were 79.0 (SEM=5.6) and significantly decreased to 27.3 (SEM=4.8; p<0.05).
Significant differences across liquid nicotine concentration and device power setting were
observed following the directed use period. Specifically, mean craving ratings were significantly
lower in the 30 mg/ml;30 W condition (M=27.3, SEM=4.8) when compared to the 10 mg/ml;30
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W condition [(M=41.5, SEM=6.0); t(20)=2.6, p<0.025]. Additionally, mean craving ratings were
significantly greater in the 30 mg/ml liquid nicotine condition at 15 W (M=41.1, SEM=6.2)
when compared to 30 W [(M=27.3, SEM=4.8); t(20)=2.8, p<0.05].
Following the ad lib use period, mean craving ratings decreased significantly over time
for each liquid nicotine concentration level at each power setting [ts(20)>3.4, ps<0.05]. For
example, at 15 W for the 10 mg/ml condition, pre-ad lib mean craving ratings were 59.2
(SEM=6.0) and significantly decreased to 35.1 (SEM=6.2; p<0.05); at 15 W for the 15 mg/ml
condition, mean craving ratings were 52.5 (SEM=6.9) and significantly decreased to 30.3
(SEM=6.5; p<0.05); at 15 W for the 30 mg/ml condition, mean craving ratings were 54.8
(SEM=6.0) and significantly decreased to 28.7 (SEM=6.7; p<0.05; See Figure 4, Panel A).
Similarly, at 30 W for the 10 mg/ml condition, pre-ad lib mean craving ratings were 55.5
(SEM=6.2) and significantly decreased to 26.9 (SEM=6.2; p<0.05); at 30 W for the 15 mg/ml
condition, mean craving ratings were 49.5 (SEM=6.3) and significantly decreased to 25.6
(SEM=5.9; p<0.05); at 30 W for the 30 mg/ml condition, mean craving ratings were 44.7
(SEM=5.4) and significantly decreased to 23.7 (SEM=5.0; p<0.05; See Figure 5, Panel B).
No significant differences were observed after the ad lib use period across liquid nicotine
conditions [ps>0.025] or device power settings [ps>0.05].
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Figure 5. Mean data (± SEM) for the Hughes-Hatsukami “Craving an e-cig/cigarette/nicotine”
item across conditions (N=21).
In all other respects, the figure is identical to Figure 2.
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Difficulty Concentrating. For the item “difficulty concentrating”, a significant threeway interaction was observed for power by time by group (see Table 2). The means (± 1 SEM)
across time (collapsed across liquid nicotine concentration) are depicted in Figure 6 Panels A
(directed use period) and B (ad lib use period). As the figure shows, mean difficulty
concentrating ratings differed significantly by device power and group prior to the directed use
period. Specifically, ratings of difficulty concentrating were significantly greater in the ECIG
user group (M=35.7, SEM=8.2) when compared to the cigarette smoker group (M=19.3,
SEM=4.5) before the directed use period in the 15 W condition [t(19)=1.7, p<0.05].
Significant differences were revealed when comparing difficulty concentrating ratings
pre- and post-directed use period within each group and power condition. For example, in the
ECIG user group at 15 W, pre-directed mean difficulty concentrating ratings were 35.7
(SEM=8.2) and significantly decreased to 20.2 [(SEM=5.3); t(10)=3.1, p<0.05]. Additionally, in
the cigarette smoker group at 30 W, pre-directed mean difficulty concentrating ratings were 23.4
(SEM=5.7) and significantly decreased to 10.4 [(SEM=5.2); t(9)=3.7, p<0.05].
No significant differences between or within groups were observed when comparing
difficulty concentrating ratings pre- and post-ad lib use period [ps>0.05], across liquid nicotine
concentration [ps>0.025], or device power setting [ps>0.05].
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Figure 6. Mean data (± SEM) for the Hughes-Hatsukami “Difficulty concentrating” item across
time by device power setting and collapsed across liquid nicotine concentration (N=21).
ECIG users (n=11; Panel A) and cigarette smokers (n=10; Panel B) completed a directed, 10puff use period and a 90-minute ad libitum use period based on liquid nicotine concentration
condition (data are collapsed across this condition) and device power setting (15 W, inverted
triangle symbol; 30 W, diamond symbol). In all other respects, the figure is identical to Figure 2.
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Drowsy. For the item “drowsiness”, a significant three-way interaction was observed for
liquid nicotine concentration by time by group [F(6,114)=3.5, p<0.05; see Table 2]. The means
(± 1 SEM) across time (collapsed across device power) are depicted in Figure 7 Panels A
(directed use period) and B (ad lib use period). As the figure shows, mean drowsiness ratings
decreased in both groups following the directed use period. However, independent samples ttests did not reveal a significant difference between groups at any relevant timepoints [ps>0.05].
Significant differences were revealed when comparing drowsiness ratings pre- and postdirected use period within the ECIG use group, collapsed across device power. For example, in
the ECIG user group at 10 mg/ml, pre-directed mean drowsiness ratings were 26.5 (SEM=6.6)
and significantly decreased to 17.1 [(SEM=4.4); t(10)=2.7, p<0.05]; at 15 mg/ml, mean
drowsiness ratings were 38.1 (SEM=8.0) and significantly decreased to 19.8 [(SEM=4.7);
t(10)=3.5, p<0.05].
No significant differences between or within groups were observed when comparing
drowsiness ratings pre- and post-ad lib use period [ps>0.05], across liquid nicotine concentration
[ps>0.025], or device power setting [ps>0.05].
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Figure 7. Mean data (± SEM) for the Hughes-Hatsukami “Drowsiness” item across time by
liquid nicotine concentration and collapsed across device power setting (N=21).
ECIG users (n=11; Panel A) and cigarette smokers (n=10; Panel B) completed a directed, 10puff use period and a 90-minute ad libitum use period. In all other respects, the figure is identical
to Figure 2.
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Hunger. For the item “hunger”, significant interactions were observed for liquid nicotine
concentration by time and device power by time (see Table 2); no significant main effect of
group or significant interactions involving the group factor were observed. Therefore, “hunger”
was re-analyzed using a three factor completely within-subject ANOVA (i.e., with no group
factor), and significant interactions were observed for liquid nicotine concentration by time
[F(6,120)=2.3, p<0.05] and device power by time [F(3,60)=2.8, p<0.05]. The means (± 1 SEM)
for all conditions across time are depicted in Figure 8 Panels A (15 W) and B (30 W). As the
figure shows, mean hunger ratings did not differ significantly by condition prior to the directed
use period. However, mean hunger ratings decreased significantly over time for some conditions
after the directed use period. Specifically, at 15 W for the 30 mg/ml condition, pre-directed mean
hunger ratings were 28.6 (SEM=6.0) and significantly decreased to 17.7 [(SEM=3.9); t(20)=2.2,
p<0.05]; at 30 W for the 15 mg/ml condition, mean hunger ratings were 43.7 (SEM=6.9) and
significantly decreased to 20.6 [(SEM=4.1); t(20)=3.3, p<0.05]; at 30 W for the 30 mg/ml
condition, mean hunger ratings were 44.3 (SEM=6.6) and significantly decreased to 22.4
[(SEM=5.0); t(20)=4.2, p<0.05].
Significant differences across device power setting were observed after the directed use
period. Specifically, within the 15 mg/ml condition, mean hunger ratings were significantly
greater 15 W condition (M=35.0, SEM=6.2) when compared to the 30 W condition [(M=20.6,
SEM=4.1); t(20)=2.3, p<0.05].
Following the ad lib use period, mean hunger ratings were significantly different across
time for some conditions. Specifically, at 15 W for the 30 mg/ml condition, pre-ad lib mean
hunger ratings were 24.1 (SEM=4.6) and significantly increased to 38.1 [(SEM=7.2); t(20)=-2.4,
p<0.05]; at 30 W for the 10 mg/ml condition, mean hunger ratings were 30.3 (SEM=5.4) and
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significantly increased to 47.0 [(SEM=6.7); t(20)=-3.2, p<0.05]; at 30 W for the 15 mg/ml
condition, mean hunger ratings were 29.7 (SEM=5.2) and significantly increased to 48.0
[(SEM=7.3; See Figure 8, Panel A); t(20)=-2.6, p<0.05].
No significant differences were observed after the ad lib use period across liquid nicotine
concentration [ps>0.025] or device power setting [ps>0.05].
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Figure 8. Mean data (± SEM) for the Hughes-Hatsukami “Hunger” item by condition and time
(N=21).
In all other respects, the figure is identical to Figure 2.
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Impatient. For the item “impatient”, a significant main effect of time was observed (see
Table 2); no significant main effect of group or significant interactions involving the group factor
were observed. Therefore, “impatient” was re-analyzed using a three factor completely withinsubject ANOVA (i.e., with no group factor), and a significant main effect of time was observed
[F(3,60)=12.6, p<0.05]. The means (± 1 SEM) for all conditions across time are depicted in
Figure 9 Panels A (15 W) and B (30 W). As the figure shows, mean impatient ratings did not
differ by condition prior to the directed use period. However, impatient ratings decreased
significantly over time for each liquid nicotine concentration level (i.e., 10, 15, 30 mg/ml) at
each power setting (i.e., 15, 30 W) after the directed use period, [ts(20)>3.9, ps<0.05]. For
example, at 15 W for the 10 mg/ml condition, pre-directed mean impatient ratings were 35.4
(SEM=6.6) and decreased to 17.5 (SEM=5.0; p<0.05); at 15 W for the 15 mg/ml condition, mean
impatient ratings were 37.7 (SEM=6.8) and decreased to 14.7 (SEM=4.6; p<0.05); at 15 W for
the 30 mg/ml condition, mean impatient ratings were 25.3 (SEM=6.3) and decreased to 13.4
(SEM=3.4; p<0.05). Similarly, at 30 W for the 10 mg/ml condition, pre-directed mean impatient
ratings were 34.1 (SEM=7.2) and decreased to 17.5 (SEM=5.3; p<0.05); at 30 W for the 15
mg/ml condition, mean impatient ratings were 26.8 (SEM=5.9) and decreased to 7.3 (SEM=2.4;
p<0.05); at 30 W for the 30 mg/ml condition, mean impatient ratings were 32.4 (SEM=6.5) and
decreased to 9.9 (SEM=2.7; p<0.05).
Significant differences across device power setting were observed after the directed use
period. Specifically, within the 15 mg/ml condition, mean impatient ratings were greater in the
15 W condition (M=14.7, SEM=4.6) when compared to the 30 W condition [(M=7.3, SEM=2.4);
t(20)=2.2, p<0.05].
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Following the ad lib use period, mean impatient ratings increased significantly over time
in the 30 mg/ml;30 W condition only. Specifically, at 30 W for the 30 mg/ml condition, pre-ad
lib mean impatient ratings were 8.3 (SEM=2.4) and increased significantly to 19.1 [(SEM=5.6;
See Figure 9, Panel B); t(20)=-2.4, p<0.05].
No significant differences were observed after the ad lib use period across liquid nicotine
concentration [ps>0.025] or device power setting [ps>0.05].
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Figure 9. Mean data (± SEM) for the Hughes-Hatsukami “Impatient” item by condition and time
(N=21).
In all other respects, the figure is identical to Figure 2.
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Irritability. For the item “irritability/frustration/anger”, a significant interaction was
observed for time by group [F(3,57)=4.8, p<0.05; see Table 2]. The means (± 1 SEM) for both
groups across time are depicted in Figure 10 Panels A (directed use period) and B (ad lib use
period). As the figure shows, mean irritability ratings (collapsed across liquid nicotine
concertation and device power) significantly differed by group prior to the directed use period.
Specifically, mean irritability ratings were significantly greater in the cigarette smoker group
(M=37.1, SEM=7.4) when compared to the ECIG user group (M=21.4, SEM=4.8) before the
directed use period [t(19)=-1.9, p<0.05].
Significant differences were revealed when comparing irritability ratings pre- and postdirected use period within each group, collapsed across liquid nicotine concentration and power
condition. For example, in the ECIG user group, pre-directed mean irritability ratings were 21.4
(SEM=4.8) and significantly decreased to 9.2 [(SEM=2.6); t(10)=3.2, p<0.05]; in the cigarette
smoker group, mean irritability ratings were 37.1 (SEM=7.4) and significantly decreased to 11.0
[(SEM=2.4); t(9)=4.0, p<0.05].
Significant differences were revealed when comparing irritability ratings pre- and post-ad
lib use period within the cigarette smoker group, collapsed across liquid nicotine concentration
and power condition. Specifically, pre-ad lib mean irritability ratings were 11.7 (SEM=4.0) and
significantly decreased to 5.2 [(SEM=3.1); t(9)=3.4, p<0.05].
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Figure 10. Mean data (± SEM) for the Hughes-Hatsukami “Irritability/frustration/anger” item by
group, collapsed across liquid nicotine concentration and device power setting (N=21).
ECIG users (n=11; diamond symbol) and cigarette smokers (n=10; hexagon symbol) completed
a directed, 10-puff use period and a 90-minute ad libitum use period. In all other respects, the
figure is identical to Figure 2.
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Restless. For the item “restlessness”, a significant main effect of time was observed (see
Table 2); no significant main effect of group or significant interactions involving the group factor
were observed. Therefore, “restlessness” was re-analyzed using a three factor completely withinsubject ANOVA (i.e., with no group factor), and a significant main effect of time was observed
[F(3,60)=9.1, p<0.05]. The means (± 1 SEM) for all conditions across time are depicted in
Figure 11 Panels A (15 W) and B (30 W). As the figure shows, mean restlessness ratings did not
differ significantly by condition prior to the directed use period. However, restlessness ratings
decreased significantly over time for some conditions after the directed use period. For example,
at 15 W for the 10 mg/ml condition, pre-directed mean restlessness ratings were 35.4 (SEM=7.4)
and decreased to 14.5 [(SEM=3.4); t(20)=3.8, p<0.05]; at 15 W for the 15 mg/ml condition,
mean restlessness ratings were 29.7 (SEM=5.6) and decreased to 15.0 [(SEM=4.7); t(20)=2.9,
p<0.05]. Similarly, at 30 W for the 10 mg/ml condition, pre-directed mean restlessness ratings
were 32.1 (SEM=6.9) and decreased to 18.5 [(SEM=4.8); t(20)=2.2, p<0.05]; at 30 W for the 30
mg/ml condition, mean restlessness ratings were 22.9 (SEM=5.1) and decreased to 11.1
[(SEM=2.7; See Figure 11, Panels A and B); t(20)=2.6, p<0.05].
No significant differences were observed after the directed use period across liquid
nicotine concentration [ps>0.025] or device power setting [ps>0.05].
No significant differences were observed after the ad lib use period across time [ps>0.05]
liquid nicotine concentration [ps>0.025] or device power setting [ps>0.05].
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Figure 11. Mean data (± SEM) for the Hughes-Hatsukami “Restlessness” item by condition and
time (N=21).
In all other respects, the figure is identical to Figure 2.
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Urge. For the item “urges to vape/smoke”, significant main effects of power and time
were observed (see Table 2); no significant main effect of group or significant interactions
involving the group factor were observed. Therefore, “urges to vape/smoke” was re-analyzed
using a three factor completely within-subject ANOVA (i.e., with no group factor), and
significant main effects of power [F(1,20)=10.5, p<0.05] and time [F(3,60)=55.9, p<0.05] were
observed. The means (± 1 SEM) for all conditions across time are depicted in Figure 12 Panels A
(15 W) and B (30 W). As the figure shows, mean urge ratings did not differ significantly by
condition prior to the directed use period. However, urges to vape/smoke decreased significantly
over time for each liquid nicotine concentration level (i.e., 10, 15, 30 mg/ml) at each power
setting (i.e., 15, 30 W) after the directed use period, [ts(20)>5.7, ps<0.05]. For example, at 15 W
for the 10 mg/ml condition, pre-directed mean urge ratings were 81.4 (SEM=4.5) and decreased
to 54.8 (SEM=5.9; p<0.05); at 15 W for the 15 mg/ml condition, mean urge ratings were 81.2
(SEM=5.5) and decreased to 43.4 (SEM=7.3; p<0.05); at 15 W for the 30 mg/ml condition, mean
urge ratings were 77.6 (SEM=6.4) and decreased to 42.1 (SEM=5.6; p<0.05). Similarly, at 30 W
for the 10 mg/ml condition, pre-directed mean urge ratings were 73.4 (SEM=6.0) and decreased
to 44.5 (SEM=5.5; p<0.05); at 30 W for the 15 mg/ml condition, mean urge ratings were 74.6
(SEM=6.0) and decreased to 38.0 (SEM=6.5; p<0.05); at 30 W for the 30 mg/ml condition, mean
urge ratings were 77.6 (SEM=5.3) and decreased to 34.7 (SEM=5.1; p<0.05).
No significant differences were observed after the directed use period across liquid
nicotine concentration [ps>0.025] or device power setting [ps>0.05].
Following the ad lib use period, mean urge ratings decreased significantly over time for
each liquid nicotine concentration level at each power setting [ts(20)>10.7, ps<0.05]. For
example, at 15 W for the 10 mg/ml condition, pre-ad lib mean urge ratings were 63.0 (SEM=5.9)
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and decreased significantly to 35.2 (SEM=6.0; p<0.05); at 15 W for the 15 mg/ml condition,
mean urge ratings were 57.6 (SEM=5.7) and decreased to 30.3 (SEM=6.5; p<0.05); at 15 W for
the 30 mg/ml condition, mean urge ratings were 58.6 (SEM=4.9) and decreased to 26.7
(SEM=5.8; p<0.05; See Figure 12, Panel A). Similarly, at 30 W for the 10 mg/ml condition, pread lib mean urge ratings were 58.2 (SEM=5.0) and decreased to 23.5 (SEM=5.1; p<0.05); at 30
W for the 15 mg/ml condition, mean urge ratings were 52.4 (SEM=5.0) and decreased to 22.4
(SEM=4.7; p<0.05); at 30 W for the 30 mg/ml condition, mean urge ratings were 46.6
(SEM=4.9) and decreased to 20.4 (SEM=4.1; p<0.05; See Figure 12, Panel B).
A significant difference across device power setting was observed after the ad lib use
period. Specifically, within the 10 mg/ml condition, mean urge ratings were greater in the 15 W
condition (M=35.2, SEM=6.0) when compared to the 30 W condition [(M=23.5, SEM=5.1);
t(20)=2.3, p<0.05].
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Figure 12. Mean data (± SEM) for the Hughes-Hatsukami “Urges to vape/smoke” item by
condition and time (N=21).
In all other respects, the figure is identical to Figure 2.
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Direct Effects of Nicotine
As displayed in Table 2, statistically significant interactions including the group factor
were observed in items Confused, Heart Pounding, and Lightheaded (see Table 2) and these
items were analyzed using a four factor mixed (within and between subjects) ANOVA. For the
remaining DEN items, no significant interactions including the group factor were observed.
Therefore, all remaining items were re-analyzed using a three factor completely within-subject
ANOVA (i.e., with no group factor). Significant main effects of group and significant
interactions including the group factor are detailed where appropriate.
Confused. For the item “confused”, a significant three-way interaction was observed for
power by time by group (see Table 2). The means (± 1 SEM) for both groups across time
(collapsed across liquid nicotine concentration) are depicted in Figure 13 Panels A (directed use
period) and B (ad lib use period). As the figure shows, confused means significantly differed by
device power and group prior to the directed use period. Specifically, in the 15 W condition, predirected mean confused ratings were significantly greater in the ECIG user group (M=9.6,
SEM=3.8) when compared to the cigarette smoker group [(M=2.1, SEM=1.6); t(19)=1.8,
p<0.05].
No significant differences were revealed within groups across time [ps>0.05].
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Figure 13. Mean data (± SEM) for the Direct Effects of Nicotine “Confused” item across time by
device power setting and collapsed across liquid nicotine concentration (N=21).
ECIG users (n=11; Panel A) and cigarette smokers (n=10; Panel B) completed a directed, 10puff use period and a 90-minute ad libitum use period based on liquid nicotine concentration
condition (data are collapsed across this condition) and device power setting (15 W, inverted
triangle symbol; 30 W, diamond symbol). Carat (^) indicates significant difference from ECIG
user group at the same time point and condition. In all other respects, the figure is identical to
Figure 2.
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Dizzy. For the item “dizzy”, a significant interaction was observed for device power by
time (see Table 2); no significant main effect of group or significant interactions involving the
group factor were observed. Therefore, “dizzy” was re-analyzed using a three factor completely
within-subject ANOVA (i.e., with no group factor), and a significant interaction was observed
for device power by time [F(3,60)=5.4, p<0.05]. The means (± 1 SEM) for all conditions across
time are depicted in Figure 14 Panels A (15 W) and B (30 W). As the figure shows, mean dizzy
ratings did not differ significantly by condition prior to the directed use period. However, mean
dizzy ratings increased significantly in the higher-powered conditions after the directed use
period. Specifically, within the 30 W condition, for the 10 mg/ml condition, pre-directed mean
dizzy ratings were 4.0 (SEM=1.7) and increased significantly to 14.4 [(SEM=5.4); t(20)=-2.6,
p<0.05]; for the 15 mg/ml condition, mean dizzy ratings were 5.3 (SEM=2.8) and increased
significantly to 18.5 [(SEM=5.2); t(20)=-2.6, p<0.05]; for the 30 mg/ml condition, mean dizzy
ratings were 7.1 (SEM=3.0) and increased significantly to 21.0 [(SEM=5.2; See Figure 14, Panel
B); t(20)=-3.1, p<0.05].
No significant differences were observed after the directed use period across liquid
nicotine concentration [ps>0.025] or device power setting [ps>0.05].
No significant differences were observed after the ad lib use period across time [ps>0.05]
liquid nicotine concentration [ps>0.025] or device power setting [ps>0.05].
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Figure 14. Mean data (± SEM) for the Direct Effects of Nicotine “Dizzy” item across conditions
(N=21).
Participants completed a directed, 10-puff use period and a 90-minute ad libitum use period in
six conditions based on liquid nicotine concentration condition (10 mg/ml, circle symbol; 15
mg/ml, square symbol; 30 mg/ml, triangle symbol) and device power setting (15 W, Panel A; 30
W Panel B). In all other respects, the figure is identical to Figure 2.
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Heart Pounding. For the item “heart pounding”, a significant four-way interaction was
observed for nicotine by power by time by group and a significant three-way interaction was
observed for nicotine by time by group (see Table 2). The means (± 1 SEM) by group and
condition across time are depicted in Figure 15 Panels A (ECIG users) and B (cigarette smokers).
Independent samples t-tests revealed a significant difference between groups following the
directed use period [p<0.05]. Specifically, within the 30 mg/ml;30 W condition, mean heart
pounding ratings were significantly greater in the ECIG user group (M=22.4, SEM=6.1) when
compared to the cigarette smoker group [(M=6.4, SEM=4.4); t(19)=2.1, p<0.05].
Following the directed use period, mean heart pounding ratings increased significantly
over time in the ECIG user group only. Specifically, in the 30 mg/ml;30 W condition, predirected mean heart pounding ratings were 3.5 (SEM=1.6) and increased significantly to 22.4
[(SEM=6.1); t(10)=-3.4, p<0.05]. Within the ECIG user group, significant differences across
liquid nicotine concentration and device power setting were observed following the directed use
period. Specifically, within the 30 W condition, mean heart pounding ratings were significantly
greater in the 30 mg/ml condition (M=22.4, SEM=6.1) when compared to the 10 mg/ml
condition [(M=7.9, SEM=3.0); t(10)=-2.7, p<0.025]. Additionally, in the 30 mg/ml condition,
mean heart pounding ratings were significantly greater in the 30 W condition (M=22.4,
SEM=6.1) when compared to the 15 W condition [(M=7.6, SEM=3.0); t(10)=-2.6, p<0.05].
Following the ad lib use period, a significant difference was observed when comparing
across device power setting in the ECIG user group only. Specifically, within the 15 mg/ml
condition, mean heart pounding ratings were significantly greater in the 30 W condition [(M=4.5,
SEM=1.6) when compared to the 15 W condition [(M=1.7, SEM=1.2); t(10)=-2.3, p<0.05].
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No significant differences were observed in the cigarette smoker group across time
[ps>0.05] liquid nicotine concentration [ps>0.025] or device power setting [ps>0.05].
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Figure 15. Mean data (± SEM) for the Direct Effects of Nicotine “Heart pounding” item across
conditions (N=21).
ECIG users (n=11; Panels A & B) and cigarette smokers (n=10; Panels C & D) completed a
directed, 10-puff use period and a 90-minute ad libitum use period based on liquid nicotine
concentration condition (10 mg/ml, circle symbol; 15 mg/ml, square symbol; 30 mg/ml, triangle
symbol) and device power setting (15 W, Panels A & C; 30 W, Panels B & D). In all other
respects, the figure is identical to Figure 2.
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Lightheaded. For the item “lightheaded”, a significant three-way interaction was
observed for power by time by group (see Table 2). The means (± 1 SEM) for both groups across
time (collapsed across liquid nicotine concentration) are depicted in Figure 16 Panels A (directed
use period) and B (ad lib use period). As the figure shows, mean lightheaded ratings differed by
group and device power following the directed use period. However, independent samples t-tests
did not reveal a significant difference between groups at this timepoint [ps>0.05].
When collapsed across liquid nicotine concentration conditions, significant differences
across time and device power setting were revealed following the directed use period. For
example, mean lightheaded ratings increased significantly over time following the directed use
period in the ECIG user group. Specifically, in the 30 W condition, pre-directed mean
lightheaded ratings were 8.4 (SEM=3.7) and increased significantly to 32.2 (SEM=7.3), [t(10)=3.8, p<0.05]. Additionally, a significant difference across device power setting was observed
following the directed use period in the ECIG user group. Specifically, mean lightheaded ratings
were significantly lower in the 15 W condition (M=20.2, SEM=6.7) when compared to the 30 W
condition [(M=32.2, SEM=7.3); t(10)=-2.6, p<0.05].
No significant differences in mean lightheaded ratings were observed following the
directed use period in the cigarette smoker group when comparing across time or device power
setting [ps>0.05].
No significant differences in mean lightheaded ratings were observed within groups
following the ad lib use period [ps>0.05].
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Figure 16. Mean data (± SEM) for the Direct Effects of Nicotine “Lightheaded” item across time
by device power setting and collapsed across liquid nicotine concentration (N=21).
ECIG users (n=11; Panel A) and cigarette smokers (n=10; Panel B) completed a directed, 10puff use period and a 90-minute ad libitum use period based on liquid nicotine concentration
condition (data are collapsed across this condition) and device power setting (15 W, inverted
triangle symbol; 30 W, diamond symbol). In all other respects, the figure is identical to Figure 2.
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Nauseous. For the item “nauseous”, a significant interaction was observed for device
power by time (see Table 2); no significant main effect of group or significant interactions
involving the group factor were observed. Therefore, “nauseous” was re-analyzed using a three
factor completely within-subject ANOVA (i.e., with no group factor), and a significant
interaction was observed for device power setting by time [F(3,60)=4.6, p<0.05]. The means (± 1
SEM) for all conditions across time are depicted in Figure 17 Panels A (15 W) and B (30 W). As
the figure shows, mean nauseous ratings did not differ by condition at the pre-directed time
point. However, mean nauseous ratings increased significantly over time in the 30 mg/ml;30 W
condition following the directed use period. Specifically, at 30 W for the 30 mg/ml condition,
pre-directed mean nauseous ratings were 2.8 (SEM=1.8) and increased significantly to 10.1
[(SEM=3.3; See Figure 17, Panel B); t(20)=-2.5, p<0.05].
A significant difference in mean nauseous ratings was observed following the directed
use period when comparing across device power setting. Specifically, in the 30 mg/ml liquid
concertation, mean nauseous ratings were greater in the 30 W condition (M=10.1, SEM=3.3)
when compared to the 15 W condition [(M=4.1, SEM=1.9); t(20)=-2.6, p<0.05].
No significant differences were observed after the ad lib use period across time
[ps>0.05], liquid nicotine concentration [ps>0.025], or device power setting [ps>0.05].
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Figure 17. Mean data (± SEM) for the Direct Effects of Nicotine “Nauseous” item across
conditions (N=21).
Participants completed a directed, 10-puff use period and a 90-minute ad libitum use period in
six conditions based on liquid nicotine concentration condition (10 mg/ml, circle symbol; 15
mg/ml, square symbol; 30 mg/ml, triangle symbol) and device power setting (15 W, Panel A; 30
W Panel B). In all other respects, the figure is identical to Figure 2.
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Nervous. For the item “nervous”, a significant main effect of time was observed (see
Table 2); no significant main effect of group or significant interactions involving the group factor
were observed. Therefore, “nervous” was re-analyzed using a three factor completely withinsubject ANOVA (i.e., with no group factor), and a significant main effect of time was observed
[F(3,60)=5.0, p<0.05]. Post-hoc t-tests revealed no significant differences across time [ps>0.05],
liquid nicotine concentration [ps>0.025], or device power setting [ps>0.05] following the
directed use period or the ad lib use period.
Weak. For the item “weak”, a significant three-way interaction was observed for liquid
nicotine concentration by device power setting by time (see Table 2); no significant main effect
of group or significant interactions involving the group factor were observed. Therefore, “weak”
was re-analyzed using a three factor completely within-subject ANOVA (i.e., with no group
factor), and a three-way interaction was observed for liquid nicotine concentration by device
power setting by time [F(6,120)=2.5, p=0.05]. The means (± 1 SEM) for all conditions across
time are depicted in Figure 18 Panels A (15 W) and B (30 W). As the figure shows, mean weak
ratings did not decrease significantly over time after the directed use period [ps>0.05].
No significant differences in weak ratings were observed after the directed use period
across liquid nicotine conditions [ps>0.025] or device power settings [ps>0.05].
Following the ad lib use period, mean weak ratings decreased significantly over time for
the 30 mg/ml;30 W condition only. Specifically, at 30 W for the 30 mg/ml condition, pre-ad lib
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use period mean weak ratings were 7.8 (SEM=2.5) and decreased significantly to 3.5 (SEM=1.5;
See Figure 18, Panel B), [t(20)=2.9, p<0.05].
No significant differences were observed after the ad lib use period across liquid nicotine
concentration [ps>0.025] or device power setting [ps>0.05].
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Figure 18. Mean data (± SEM) for the Direct Effects of Nicotine “Weak” item across conditions
(N=21).
Participants completed a directed, 10-puff use period and a 90-minute ad libitum use period in
six conditions based on liquid nicotine concentration condition (10 mg/ml, circle symbol; 15
mg/ml, square symbol; 30 mg/ml, triangle symbol) and device power setting (15 W, Panel A; 30
W Panel B). In all other respects, the figure is identical to Figure 2.
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Direct Effects of ECIG Use
The direct effects of ECIG use was administered after ECIG use only. Therefore, the
factor of time was not included in analysis and the directed and ad lib use periods were analyzed
separately. The liquid concentration, power, and group factors are the same as all other measures.
As displayed in Table 6, statistically significant interactions including the group factor were
observed in items Right Now (directed use period only) and Sick (ad lib period only), and these
items were analyzed using a three factor, mixed (within and between subjects) ANOVA. For the
remaining items, no significant interactions including the group factor were observed. Therefore,
all remaining items were re-analyzed using a two factor completely within-subject ANOVA (i.e.,
with no group factor). Significant main effects of group and significant interactions including the
group factor are detailed where appropriate.
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Table 6. Statistical Analysis Results for Three-Factor Mixed Analysis of Variance (Directed + ad
libitum use periods).
Nicotine

DE ECIG use
Awake
Directed
Ad libitum
Calm
Directed
Ad libitum
Concentrate
Directed
Ad libitum
Dizzy
Directed
Ad libitum
Pleasant
Directed
Ad libitum
Reduce
Hunger
Directed
Ad libitum
Right Now
Directed
Ad libitum
Satisfy
Directed
Ad libitum
Sick
Directed
Ad libitum
Taste Good
Directed
Ad libitum

Power

Nicotine *
Power

Nicotine *
Group

Power *
Group

Nicotine *
Power *
Group
F
ηp2

F

ηp2

F

ηp2

F

ηp2

F

η p2

F

ηp2

0.4
0.3

.02
.02

2.9
1.9

.13
.09

0.1
1.3

.01
.06

0.2
1.2

.01
.06

0.1
0.3

.01
.02

0.6
0.2

.03
.01

0.2
0.1

.01
.00

0.8
0.5

.04
.03

0.3
0.6

.02
.03

1.2
0.2

.06
.01

0.0
1.0

.00
.05

3.1
0.1

.14
.00

0.2
1.5

.01
.08

0.8
0.3

.04
.01

0.1
0.4

.00
.02

0.0
0.6

.00
.03

0.2
0.6

.01
.03

1.6
0.4

.08
.02

1.8
2.5

.08
.12

16.1
2.1

.46
.10

0.5
0.0

.03
.00

1.5
1.7

.07
.08

9.1
1.6

.32
.08

0.2
0.8

.01
.04

7.1
3.8

.27
.17

0.9
0.0

.05
.00

0.3
0.6

.02
.03

0.8
0.1

.04
.00

0.9
0.2

.05
.01

1.0
0.2

.05
.01

4.1
3.6

.18
.16

0.1
0.0

.01
.00

1.7
1.3

.08
.06

0.1
3.0

.00
.14

0.1
2.5

.01
.12

1.0
0.4

.05
.02

8.3
1.0

.30
.05

35.6
11.6

.65
.38

1.1
1.7

.05
.08

0.0
1.8

.00
.09

8.5
0.1

.31
.01

2.8
1.5

.13
.07

1.5
0.3

.07
.02

1.4
0.6

.07
.03

1.1
4.2

.05
.18

0.9
0.7

.05
.03

0.0
0.0

.00
.00

2.9
1.8

.13
.09

2.5
1.9

.12
.09

0.8
0.3

.04
.02

0.8
2.1

.04
.10

0.4
1.8

.02
.09

1.5
5.3

.07
.22

1.4
0.8

.07
.04

4.0
1.7

.18
.08

0.2
6.6

.01
.26

0.0
1.7

.00
.08

2.1
0.0

.10
.00

0.0
0.1

.00
.01

1.3
0.9

.06
.05

df N=(2,38); df P=(1,19); df N*P=(2,38); df N*G=(2,38); df P*G=(1,19); df N*P*G=(2,38)
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Dizzy. For the item “did the e-cig make you dizzy?”, a significant interaction for power
by group [F(1,19)=9.1, p<0.05] and a main effect of power [F(1,19)=16.1, p<0.05; see Table 6]
were observed following the directed use period. The means (+ 1 SEM) for each group
(collapsed across liquid nicotine concentration) following the directed use period are depicted in
Figure 19 Panels A (ECIG users) and B (cigarette smokers). As the figure shows, differences in
mean “did the e-cig make you dizzy?” ratings based on device power setting were greater in the
ECIG user group when compared to the cigarette smoker group. Independent samples t-tests
revealed a significant difference between groups in the 30 mg/ml;30 W condition [t(19)=2.6,
p<0.05] following the directed use period.
Following the directed use period, significant differences across device power setting
were revealed within the ECIG user group. Specifically, within the 10 mg/ml condition, mean
dizzy ratings were significantly greater in the 15 W condition (M=18.1, SEM=7.2) when
compared to the 30 W condition [(M=34.3, SEM=9.2); t(10)=-2.6, p<0.05]; at 15 mg/ml, mean
dizzy ratings were significantly greater in the 15 W condition (M=21.7, SEM=7.4) when
compared to the 30 W condition [(M=41.3, SEM=10.9); t(10)=-3.1, p<0.05]; at 30 mg/ml, mean
dizzy ratings were significantly greater in the 15 W condition (M=29.8, SEM=7.8) when
compared to the 30 W condition [(M=58.0, SEM=9.3); t(10)=-3.0, p<0.05]. Additionally, a
significant difference was revealed when comparing across liquid nicotine concentrations within
the ECIG user group. Within the 30 W condition, mean dizzy ratings were significantly greater
in the 10 mg/ml condition (M=34.3, SEM=9.2) when compared to the 30 mg/ml condition
[(M=58.0, SEM=9.3); t(10)=-2.9, p<0.025] following the directed use period.
No significant differences were observed within the cigarette smoker group across liquid
nicotine concentration [ps>0.025] or device power setting [ps>0.05].
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Figure 19. Mean data (+ SEM) for the Direct Effects of ECIG use “Did the e-cig make you
dizzy?” item by liquid nicotine concentration and device power setting conditions (N=21).
ECIG users (n=11; Panel A) and cigarette smokers (n=10; Panel B) completed a directed, 10puff use period and a 90-minute ad libitum use period (not pictured) in six conditions based on
liquid nicotine concentration condition (10 mg/ml, 15 mg/ml, 30 mg/ml) and device power
setting (15 W, white bars; 30 W, black bars). Carat (^) indicates significant difference from
ECIG user group at the same time point and condition. Number sign (#) indicates significant
difference from 10 mg at same time point. Asterisks (*) indicate significant difference from 15
W at same time point.
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Pleasant. For the item “was the e-cig pleasant?”, a significant main effect of liquid
nicotine concentration was observed following the directed use period and the ad lib use period
(see Table 6); no significant main effect of group or significant interactions involving the group
factor were observed. Therefore, “was the e-cig pleasant?” was re-analyzed using a two factor
completely within-subject ANOVA (i.e., with no group factor), and a significant main effect of
liquid nicotine concentration was observed following the directed use period [F(2,40)=7.4,
p<0.05] and the ad lib use period [F(2,40)=4.0, p<0.05]. The means (+ 1 SEM) for all conditions
are depicted in Figure 20 Panels A (post-directed use period) and B (post-ad lib use period). As
the figure shows, “was the e-cig pleasant?” means decreased as liquid nicotine concentration
increased following the directed period.
A significant difference across liquid nicotine concentration was observed after the
directed use period. Specifically, within the 30 W condition, mean pleasant ratings were
significantly greater in the 10 mg/ml condition (M=63.2, SEM=5.7) when compared to the 30
mg/ml condition [(M=43.5, SEM=6.2); t(20)=2.6, p<0.025].
No significant differences were observed after the ad lib use period across liquid nicotine
concentration [ps>0.025] or device power setting [ps>0.05].
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Figure 20. Mean data (+ SEM) for the Direct Effects of ECIG use “Was the e-cig pleasant?” item
by liquid nicotine concentration and device power setting conditions (N=21).
Participants completed a directed, 10-puff use period (Panel A) and a 90-minute ad libitum use
period (Panel B) in six conditions based on liquid nicotine concentration condition (10 mg/ml; 15
mg/ml; 30 mg/ml) and device power setting (15 W, gray bars; 30 W, black bars). Number sign
(#) indicates significant difference from 10 mg at same time point. Asterisks (*) indicate
significant difference from 15 W at same liquid nicotine concentration.

PHYSIO AND SUBJECTIVE EFFECTS PROTONATED NICOTINE

111

Reduce hunger. For the item “did the e-cig reduce your hunger for food?”, a significant
main effect of liquid nicotine concentration was observed following the directed use period and
the ad lib use period (see Table 6); no significant main effect of group or significant interactions
involving the group factor were observed. Therefore, “did the e-cig reduce your hunger for
food?” was re-analyzed using a two factor completely within-subject ANOVA (i.e., with no
group factor), and a significant main effect of liquid nicotine concentration was observed
following the directed use period [F(2,40)=4.4, p<0.05] and the ad lib use period [F(2,40)=3.6,
p<0.05]. The means (+ 1 SEM) for all conditions are depicted in Figure 21 Panels A (postdirected use period) and B (post-ad lib use period). As the figure shows, mean “did the e-cig
reduce your hunger for food?” ratings differed by condition.
Following the directed use period, significant differences in mean reduced hunger ratings
were observed across liquid nicotine conditions. Specifically, in the 15 W condition, mean
reduced hunger ratings were significantly lower in the 10 mg/ml condition (M=15.1, SEM=4.2)
when compared to the 15 mg/ml condition [(M=33.3, SEM=7.0); t(20)=-2.6, p<0.025] and to the
30 mg/ml condition [(M=32.1, SEM=7.1); t(20)=-2.7, p<0.025]. No significant differences in
mean reduced hunger ratings were observed after the directed use period across device power
settings [ps>0.05].
Following the ad lib use period, a significant difference across liquid nicotine
concentration was observed. Specifically, in the 15 W conditions, mean reduced hunger ratings
were significantly lower in the 10 mg/ml liquid nicotine condition (M=17.8, SEM=4.9) when
compared to the 15 mg/ml condition [(M=28.3, SEM=6.1); t(20)=-2.6, p<0.025]. No significant
differences were observed after the ad lib use period across device power setting [ps>0.05].
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Figure 21. Mean data (+ SEM) for the Direct Effects of ECIG use “Did the e-cig reduce your
hunger for food?” item by liquid nicotine concentration and device power setting conditions
(N=21).
In all other respects, the figure is identical to Figure 20.
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Right now. For the item “would you like to use another e-cig right now?”, a significant
interaction was observed for power by group following the directed use period (see Table 6). The
means (+ 1 SEM) for each group (collapsed across liquid nicotine concentration) following the
directed use period are depicted in Figure 22 Panels A (ECIG users) and B (cigarette smokers).
As the figure shows, differences in mean “would you like to use another e-cig right now?”
ratings based on device power setting were greater in the ECIG user group when compared to the
cigarette smoker group. However, independent samples t-tests did not reveal a significant
difference between groups [ps>0.05].
Significant differences across device power setting were revealed within groups
following the directed use period. Specifically, in the ECIG user group, mean right now ratings
were significantly greater in the 15 W condition (M=55.5, SEM=6.1) when compared to the 30
W condition [(M=35.8, SEM=6.6); t(10)=5.6, p<0.05]. Additionally, in the cigarette smoker
group, mean right now ratings were significantly greater in the 15 W condition (M=49.3,
SEM=7.5) when compared to the 30 W condition [(M=42.5, SEM=8.1); t(9)=2.6, p<0.05].
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Figure 22. Mean data (+ SEM) for the Direct Effects of ECIG use “Would you like to use
another e-cig right now?” item across conditions (N=21).
ECIG users (n=11; Panel A) and cigarette smokers (n=10; Panel B) completed a directed, 10puff use period and a 90-minute ad libitum use period (not pictured) in six conditions based on
liquid nicotine concentration condition (collapsed across this condition) and device power setting
(15 W, white bars; 30 W, black bars). In all other respects, the figure is identical to Figure 19.
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Satisfy. For the item “was the e-cig satisfying?”, a significant interaction was observed
for liquid nicotine concentration by power following the ad lib use period (see Table 6); no
significant main effect of group or significant interactions involving the group factor were
observed. Therefore, “was the e-cig satisfying?” was re-analyzed using a two factor completely
within-subject ANOVA (i.e., with no group factor), and a significant interaction was observed
for liquid nicotine concentration by power [F(2,40)=3.3, p<0.05] following the ad lib use period.
The means (+ 1 SEM) for all conditions are depicted in Figure 23 Panels A (post-directed use
period) and B (post-ad lib use period). No significant differences in mean “was the e-cig
satisfying?” ratings were observed after the directed use period across liquid nicotine conditions
[ps>0.025] or device power settings [ps>0.05].
A significant difference across device power setting was observed following the ad lib
use period. Specifically, mean satisfy ratings were significantly different when comparing the 10
mg/ml liquid nicotine condition at 15 W (M=51.9, SEM=5.3) and 30 W [(M=65.0, SEM=5.3);
t(20)=-2.3, p<0.05]. No significant differences were observed after the ad lib use period across
liquid nicotine concentration [ps>0.025].
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Figure 23. Mean data (+ SEM) for the Direct Effects of ECIG use “Was the e-cig satisfying?”
item by liquid nicotine concentration and device power setting conditions (N=21).
In all other respects, the figure is identical to Figure 20.
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Sick. For the item “did the e-cig make you sick?”, a significant interaction was observed
for power by group following the ad lib use period (see Table 6). However, independent
samples t-tests did not reveal a significant difference between groups [ps>0.05]. Additionally,
when collapsed across liquid nicotine concentration conditions, post-hoc tests did not reveal
significant differences within groups [ps>0.05].
Taste good. For the item “did the e-cig taste good?”, a significant main effect of liquid
nicotine concentration was observed following the directed use period, as well as a significant
main effect of power following the ad lib use period (see Table 6); no significant main effect of
group or significant interactions involving the group factor were observed. Therefore, “did the ecig taste good?” was re-analyzed using a two factor completely within-subject ANOVA (i.e.,
with no group factor), and a significant main effect of liquid nicotine concentration [F(2,40)=3.6,
p<0.05] was observed following the directed use period, as well as a main effect of device power
[F(1,20)=6.8, p<0.05] following the ad lib use period. The means (+ 1 SEM) for all conditions
are depicted in Figure 24 Panels A (post-directed use period) and B (post-ad lib use period).
No significant differences in mean taste good ratings were observed after the directed use
period across liquid nicotine concentration [ps>0.025] or device power setting [ps>0.05].
A significant difference across device power setting was observed following the ad lib
use period. Specifically, mean taste good ratings were significantly different when comparing the
10 mg/ml liquid nicotine condition at 15 W (M=58.8, SEM=5.8) and 30 W [(M=71.5,
SEM=3.8); t(20)=-2.1, p<0.05]. No significant differences were observed after the ad lib use
period across liquid nicotine concentration [ps>0.025].
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Figure 24. Mean data (+ SEM) for the Direct Effects of ECIG use “Did the e-cig taste good?”
item by liquid nicotine concentration and device power setting conditions (N=21).
In all other respects, the figure is identical to Figure 20.
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General Labeled Magnitude Score
The general labeled magnitude score (gLMS) was administered after ECIG use only.
Therefore, the factor of time was not included in analysis and the directed and ad lib use periods
were analyzed separately. The liquid concentration, power, and group factors are the same as all
other measures. No statistically significant interactions including the group factor were observed
(see Table 7). Therefore, all items were re-analyzed using a two factor completely within-subject
ANOVA (i.e., with no group factor or time factor), and these results are reported here (see Table
8).
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Table 7. Statistical Analysis Results for Three-Factor Mixed Analysis of Variance (Directed + ad
libitum use periods).
Nicotine

gLMS
Flavor
Directed
Ad libitum
Harshness
Directed
Ad libitum
Throat Hit
Directed
Ad libitum

Power

Nicotine *
Power

Nicotine *
Group

Power *
Group

Nicotine *
Power *
Group
F
ηp2

F

ηp2

F

ηp2

F

ηp2

F

ηp2

F

ηp2

0.7
1.6

.04
.08

17.2
12.9

.48
.40

1.1
0.8

.05
.04

0.4
0.6

.02
.03

1.3
3.3

.06
.15

0.2
1.3

.01
.06

20.7
8.3

.52
.30

3.5
1.8

.16
.09

0.4
1.4

.02
.07

0.9
0.1

.05
.00

0.7
0.1

.04
.01

0.2
0.2

.01
.01

21.3
8.2

.53
.30

14.8
8.7

.44
.32

1.3
2.3

.07
.11

0.5
0.1

.03
.01

1.1
0.5

.06
.03

0.3
0.5

.01
.03

df N=(2,38); df P=(1,19); df N*P=(2,38); df N*G=(2,38); df P*G=(1,19); df N*P*G=(2,38)

Table 8. Statistical Analysis Results for Two-Factor Mixed Analysis of Variance (Directed + ad
libitum use periods).
Nicotine
gLMS
Flavor
Directed
Ad libitum
Harshness
Directed
Ad libitum
Throat Hit
Directed
Ad libitum

Power

Nicotine *
Power
F
ηp2

F

ηp2

F

ηp2

.71
1.5

.03
.07

16.5
11.0

.45
.36

1.1
.81

.05
.04

21.3
8.6

.52
.30

3.4
1.9

.15
.09

0.38
1.5

.02
.07

22.1
8.7

.53
.30

14.4
8.8

.42
.31

1.3
2.2

.06
.10

df N=(2,40); df P=(1,20); df N*P=(2,40)
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Flavor. For ratings of flavor, a significant main effect of power was observed following
the directed use period and the ad lib period (see Table 8). The means (+ 1 SEM) for all
conditions are depicted in Figure 25 Panels A (post-directed use period) and B (post-ad lib use
period). As the figure shows, significant differences across device power setting were observed
after the directed and ad lib use periods.
Following the directed use period, within the 15 mg/ml condition, mean flavor ratings
were significantly greater in the 30 W condition (M=37.7, SEM=5.3) when compared to the 15
W condition [(M=26.7, SEM=3.4); t(20)=-2.5, p<0.05]. Additionally, in the 30 mg/ml condition,
mean flavor ratings were significantly greater in the 30 W condition (M=37.6, SEM=5.1) when
compared to the 15 W condition [(M=28.4, SEM=6.0); t(20)=-2.5, p<0.05].
Following the ad lib use period, within the 15 mg/ml condition, mean flavor ratings were
significantly greater in the 30 W condition (M=35.7, SEM=5.3) when compared to the 15 W
condition [(M=24.1, SEM=3.6); t(20)=-2.9, p<0.05]. No significant differences were observed
across liquid nicotine concentration [ps>0.025].
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Figure 25. Mean data (+ SEM) for the General Labeled Magnitude Scale “Flavor sensation” item
by liquid nicotine concentration and device power setting conditions (N=21).
Participants completed a directed, 10-puff use period (Panel A) and a 90-minute ad libitum use
period (Panel B) in six conditions based on liquid nicotine concentration condition (10 mg/ml; 15
mg/ml; 30 mg/ml) and device power setting (15 W, white bars; 30 W, black bars). Number sign
(#) indicates significant difference from 10 mg at same time point. Asterisks (*) indicate
significant difference from 15 W at same liquid nicotine concentration.
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Harshness. For ratings of harshness, a significant main effect of liquid nicotine
concentration was observed following the directed use period and the ad lib use period (see
Table 8). The means (+ 1 SEM) for all conditions are depicted in Figure 26 Panels A (postdirected use period) and B (post-ad lib use period). As the figure shows, harshness ratings
increased as liquid nicotine concentration and device power setting increased.
Following the directed use period, in the 10 mg/ml condition, mean harshness ratings
were significantly greater in the 30 W condition (M=25.2, SEM=5.3) when compared to the 15
W condition [(M=14.6, SEM=3.0); t(20)=-3.2, p<0.05]. Significant differences across liquid
nicotine concentration were also observed after the directed use period. Specifically, at 15 W,
mean harshness ratings were greater in the 30 mg/ml condition (M=31.4, SEM=5.2) when
compared to the 10 mg/ml condition [(M=14.6, SEM=3.0); t(20)=-3.8, p<0.025]. Additionally, at
30 W, mean harshness ratings were significantly lower in the 10 mg/ml condition (M=25.2,
SEM=5.3) when compared to the 15 mg/ml condition [(M=31.8, SEM=5.7); t(20)=-2.8,
p<0.025] and to the 30 mg/ml condition [(M=41.7, SEM=6.4); t(20)=-4.9, p<0.025].
Following the ad lib use period, significant differences across device power setting and
liquid nicotine concentration were observed. Within the 10 mg/ml condition, mean harshness
ratings were significantly greater in the 30 W condition (M=27.7, SEM=5.6) when compared to
the 15 W condition [(M=16.4, SEM=4.1); t(20)=-2.7, p<0.05]. Comparing across liquid nicotine
concentration, at 15 W, mean harshness ratings were significantly greater in the 30 mg/ml
condition (M=32.4, SEM=6.0) when compared to the 10 mg/ml condition [(M=16.4, SEM=4.1);
t(20)=-2.9, p<0.025]. Similarly, at 30 W, mean harshness ratings were significantly greater in the
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30 mg/ml condition (M=38.0, SEM=5.9) when compared to the 10 mg/ml condition [(M=27.7,
SEM=5.6); t(20)=-3.8, p<0.025].

PHYSIO AND SUBJECTIVE EFFECTS PROTONATED NICOTINE

125

Figure 26. Mean data (+ SEM) for the General Labeled Magnitude Scale “Harshness” item by
liquid nicotine concentration and device power setting conditions (N=21).
In all other respects, the figure is identical to Figure 25.
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Throat Hit. For ratings of throat hit, a significant main effect of nicotine concentration
was observed following the directed use period and the ad lib use period (see Table 8).
Additionally, a significant main effect of power was observed following the directed use period
and the ad lib use period (see Table 8). The means (+ 1 SEM) for all conditions are depicted in
Figure 27 Panels A (post-directed use period) and B (post-ad lib use period). As the figure
shows, throat hit ratings increased as liquid nicotine concentration and device power setting
increased following ECIG use.
Following the directed use period, within the 10 mg/ml liquid nicotine concentration
condition, mean throat hit ratings were significantly greater in the 30 W condition (M=32.1,
SEM=5.3) when compared to the 15 W condition (M=14.3, SEM=3.1) after the directed use
period, [t(20)=-4.7, p<0.05]. Additionally, within the 30 mg/ml liquid nicotine concentration
condition, mean throat hit ratings were significantly greater in the 30 W condition (M=47.0,
SEM=5.3) when compared to the 15 W condition [(M=34.8, SEM=5.2); t(20)=-3.2, p<0.05].
Significant differences across liquid nicotine concentration were also observed after the directed
use period. Specifically, within the 15 W condition, mean throat hit ratings were lower in the 10
mg/ml condition (M=14.3, SEM=3.1) when compared to the 15 mg/ml condition [(M=27.4,
SEM=5.3); t(20)=-4.0, p<0.05] and to the 30 mg/ml condition [(M=34.8, SEM=5.2); t(20)=-4.7,
p<0.05]. Additionally, within the 30 W condition, mean throat hit ratings were significantly
greater in the 30 mg/ml condition (M=47.0, SEM=5.3) when compared to the 10 mg/ml
condition [(M=32.1, SEM=5.3); t(20)=-5.2, p<0.025].
Following the ad lib use period, significant differences across device power setting and
liquid nicotine concentration were observed. Similar to the pattern observed following the
directed use period, throat hit ratings increased as liquid nicotine concentration and device power
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setting increased following the ad lib user period. Within the 10 mg/ml condition, mean throat
hit ratings were significantly greater in the 30 W condition (M=32.3, SEM=5.6) when compared
to the 15 W condition [(M=19.5, SEM=4.4); t(20)=-3.6, p<0.05]. Additionally, within the 30
mg/ml condition, mean throat hit ratings were significantly greater in the 30 W condition
(M=41.6, SEM=5.4) when compared to the 15 W condition [(M=32.5, SEM=6.0); t(20)=-2.8,
p<0.05]. Comparing across liquid nicotine concentration, within the 15 W condition, mean throat
hit ratings were greater in the 30 mg/ml condition (M=32.5, SEM=6.0) when compared to the 10
mg/ml condition [(M=19.5, SEM=4.4); t(20)=-3.0, p<0.025]. Similarly, within the 30 W
condition, mean throat hit ratings were significantly greater in the 30 mg/ml condition (M=41.6,
SEM=5.4) when compared to the 10 mg/ml condition [(M=32.3, SEM=5.6); t(20)=-4.2,
p<0.025].
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Figure 27. Mean data (+ SEM) for the General Labeled Magnitude Scale “Throat hit” item by
liquid nicotine concentration and device power setting conditions (N=21).
In all other respects, the figure is identical to Figure 25.
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Discussion
Overview
This study examined the interaction of protonated nicotine liquid concentration and
device power output on physiological measures (plasma nicotine concentration, heart rate), user
behavior (puff topography) and subjective effects. Previous research has established that freebase
liquid nicotine concentration and device power output influence plasma nicotine concentration
and other outcome measures related to ECIG use. However, this study is the first to manipulate
nicotine concentration and device power systematically when the ECIG liquid contains a
majority of protonated nicotine. Findings from the present study suggest that liquid nicotine
concentration and device power influence ECIG nicotine delivery, user behavior, and subjective
effects associated with use of ECIG devices containing protonated nicotine. For example,
increases in one or both of these factors lead to increases in plasma nicotine concentration. This
effect, also seen with liquids that are primarily freebase nicotine (Hiler et al., 2020), has
implications regarding the consequences that might be expected in response to ECIG regulations
that attempt to control nicotine delivery by limiting one factor (e.g., liquid protonated nicotine
concentration) when other factors (e.g., device power and/or puff duration) are unregulated.
Results from this study support the combination of regulations aimed at limiting the rate at which
nicotine is emitted from the ECIG (nicotine flux; Shihadeh & Eissenberg, 2015) and regulations
aimed at limiting puff duration. By limiting nicotine flux and puff duration simultaneously,
regulators may gain control over the nicotine delivery of ECIGs.
Physiological Effects
In this study, physiological effects involved measurement of participant plasma nicotine
concentration and heart rate. Overall, plasma nicotine concentration and HR significantly
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increased in all conditions after ECIG use, indicating that all combinations of liquid nicotine
concentration and device power reliably delivered physiologically active nicotine doses.
With respect to how liquid nicotine concentration influenced plasma nicotine, following
the directed use period (i.e., 10 puffs, 30 sec IPI), within the 15 W conditions, the mean increase
in plasma nicotine concentration was more pronounced (but not significantly so) in the 30 mg/ml
nicotine condition (M=14.0, SD=12.7) when compared to the 10 mg/ml nicotine condition
(M=9.1, SD=7.7). This observation that higher liquid nicotine concentration is associated with
greater plasma nicotine concentration is consistent with previous studies of freebase nicotine
ECIG liquids. Specifically, increases in liquid nicotine concentration were associated with
significantly greater increases in plasma nicotine concentration (Hiler et al., 2017, 2020;
Dawkins et al., 2016). Examining the effect of device power setting (independent of liquid
nicotine concentration), within the 10 mg/ml nicotine condition, the observed mean increase in
plasma nicotine concentration was more pronounced (but not significantly so) in the 30 W
condition (M=11.7, SD=10.0) when compared to the 15 W condition (M=9.1, SD=7.7). This
observation that greater device power output is associated with higher plasma nicotine
concentration is consistent with previous studies of ECIGs. Specifically, increases in device
power output were associated with significantly greater increases in plasma nicotine
concentration (Hiler et al., 2020; Wagener et al., 2017). Looking at the combined effects of
liquid nicotine concentration and device power output, in the condition with highest liquid
nicotine concentration and higher device power setting (30 mg/ml;30 W), the mean (SD)
increase in plasma nicotine concentration following 10 puffs was 19.1 ng/ml (19.2), the highest
nicotine plasma concentration observed following the directed use period (see Figure 2; p. 53).
Additionally, the mean increase in plasma nicotine concentration observed in the 30 mg/ml;30 W
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condition was significantly greater when compared to the increase observed in the 10 mg/ml;15
W condition [(M=9.1, SD=7.7); t(20)=-3.0, p<0.05]. In sum, these observations that plasma
nicotine concentration increased following 10 puffs demonstrate that liquid nicotine
concentration and device power setting alone and in combination influence the nicotine delivery
of ECIGs containing protonated nicotine, making attending to both of these factors essential to
any regulatory action(s) aimed at limiting the nicotine delivery of ECIGs.
Similarly, HR significantly increased in all conditions during ECIG use, confirming the
physiological effects of the observed increases in plasma nicotine. With respect to how liquid
nicotine concentration influenced HR, following the directed use period (i.e., 10 puffs, 30 sec
IPI), within the 15 W conditions, the mean increase in HR was more pronounced (but not
significantly so) in the 30 mg/ml nicotine condition (M=13.6, SD=8.0) when compared to the 10
mg/ml nicotine condition (M=11.1, SD=6.3). This observation that higher liquid nicotine
concentration is associated with increased HR is consistent with a previous study of freebase
nicotine ECIG liquids. Specifically, increases in liquid nicotine concentration were associated
with significantly greater increases in HR (Hiler et al., 2017). Examining the effect of device
power setting (independent of liquid nicotine concentration), within the 10 mg/ml nicotine
condition, the observed mean increase in HR was more pronounced (but not significantly so) in
the 30 W condition (M=13.2, SD=9.3) when compared to the 15 W condition (M=11.1, SD=6.3).
This observation that greater device power output is associated with increased HR is consistent
with a previous study of ECIGs. Specifically, increases in device power output were associated
with significantly greater increases in HR (Hiler et al., 2020). Looking at the combined effects of
liquid nicotine concentration and device power output, in the condition with highest liquid
nicotine concentration and higher device power setting (30 mg/ml;30 W), the mean (SD)
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increase in HR following 10 puffs was 19.3 bpm (8.7), the highest HR observed following the
directed use period (see Figure 3; p. 56). Additionally, the mean increase in HR observed in the
30 mg/ml;30 W condition was significantly greater when compared to the HR increase observed
in the 10 mg/ml;15 W condition [(M=11.1, SD=6.3); t(20)=-6.2, p<0.05]. In sum, these
observations that HR increased following 10 puffs demonstrate that liquid nicotine concentration
and device power setting alone and in combination influence the nicotine delivery and,
correspondingly, the cardiovascular response of ECIGs containing protonated nicotine.
Significant differences in plasma nicotine concentration following ECIG use were not
detected between liquid nicotine concentration or device power output following the ad lib use
period, suggesting that the effects of these two factors on nicotine delivery may be influenced by
user behavior.
Puff Topography
In this study, puff topography involved measurement of puff count and duration, as well
as inter-puff interval (IPI) and average flow rate. Significant differences were observed in puff
duration and IPI (see Tables 3-5, p. 58-59), indicating that liquid nicotine concentration and
device power influenced puff topography during ECIG use.
Significant differences in puff duration during the directed use period based on liquid
nicotine concentration and device power setting were observed. With respect to how liquid
nicotine concentration influenced puff duration, during the directed use period (i.e., 10 puffs, 30
sec IPI), within the 15 W conditions, mean puff duration was significantly shorter in the 30
mg/ml nicotine condition (M=2.9, SD=0.2) when compared to the 10 mg/ml nicotine condition
(M=3.7, SD=0.3). This observation that higher liquid nicotine concentration is associated with
shorter puff duration is consistent with previous studies of freebase nicotine ECIG liquids
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(Dawkins et al., 2016, 2018; Hiler et al., 2017). Examining the effect of device power setting
(independent of liquid nicotine concentration), within the 10 mg/ml nicotine condition, the
observed mean puff duration was significantly shorter in the 30 W condition (M=2.5, SD=0.2)
when compared to the 15 W condition (M=3.7, SD=0.3). This observation that greater device
power output is associated with shorter puff duration is consistent with previous studies of
ECIGs (Farsalinos et al., 2018; Hiler et al., 2020). Looking at the combined effects of liquid
nicotine concentration and device power output, in the condition with highest liquid nicotine
concentration and higher device power setting (30 mg/ml;30 W), the mean (SD) puff duration
was 2.0 sec (0.2), the shortest puff duration observed during the directed use period (see Table 4;
p. 59). Additionally, the mean puff duration observed in the 30 mg/ml;30 W condition was
significantly shorter when compared to the puff duration observed in the 10 mg/ml;30 W
condition (M=2.5, SD=0.2) and the 30 mg/ml;15 W condition (M=2.9, SD=0.2; see Results
section).
Similarly, changes in IPI during the ad lib use period based on liquid nicotine
concentration and device power setting were observed. With respect to how liquid nicotine
concentration influenced IPI, during the ad lib use period, within the 15 W conditions, mean IPI
was longer (but not significantly so) in the 30 mg/ml nicotine condition (M=187.0, SD=23.6)
when compared to the 15 mg/ml nicotine condition (M=126.8, SD=13.2), and the 10 mg/ml
nicotine condition (M=184.7, SD=47.3). This observation that higher liquid nicotine
concentration is associated with longer IPI is consistent with previous ECIG research using
freebase nicotine ECIG liquids. Specifically, increases in liquid nicotine concentration were
associated with significantly longer IPI (Dawkins et al., 2018). Examining the effect of device
power setting (independent of liquid nicotine concentration), within the 30 mg/ml nicotine
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condition, the observed mean IPI was significantly longer in the 30 W condition (M=298.0,
SD=65.0) when compared to the 15 W condition (M=187.0, SD=23.6). This observation that
greater device power output is associated with longer IPI is consistent with previous studies of
ECIGs (Kimber et al., 2021, see suppl. Figure S1). Looking at the combined effects of liquid
nicotine concentration and device power output, in the condition with highest liquid nicotine
concentration and higher device power setting (30 mg/ml;30 W), the mean (SD) IPI was 298.0
sec (65.0), the longest IPI observed during the ad lib use period (see Table 4; p. 59).
Additionally, the mean IPI observed in the 30 mg/ml;30 W condition was significantly longer
when compared to the IPI observed in the 10 mg/ml;15 W condition [(M=184.7, SD=47.3);
t(18)=2.4, p<0.05].
Significant differences in puff count during the ad lib use period were observed within
the ECIG user group only (see Group Differences, below). Nonetheless, non-significant changes
in puff count based on liquid nicotine concentration and device power setting were observed.
With respect to how liquid nicotine concentration influenced puff count, during the ad lib use
period, within the 15 W conditions, mean puff count was lower (but not significantly so) in the
30 mg/ml nicotine condition (M=35.4, SD=7.2) when compared to the 10 mg/ml nicotine
condition (M=50.1, SD=12.9). This observation that higher liquid nicotine concentration is
associated with fewer puffs is consistent with previous studies of freebase nicotine ECIG liquids
(Dawkins et al., 2016, 2018; Hiler et al., 2020). Examining the effect of device power setting
(independent of liquid nicotine concentration), within the 10 mg/ml nicotine condition, the
observed mean puff count was lower (but not significantly so) in the 30 W condition (M=44.1,
SD=8.3) when compared to the 15 W condition (M=50.1, SD=12.9). This observation that
greater device power output is associated with fewer puffs is consistent with previous studies of
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ECIGs (Farsalinos et al., 2018). Looking at the combined effects of liquid nicotine concentration
and device power output, in the condition with highest liquid nicotine concentration and higher
device power setting (30 mg/ml;30 W), the mean (SD) puff count was 34.6 (11.0), the fewest
puffs observed during the ad lib use period (see Table 4; p. 59).
In sum, these observations of changes in puff topography during ECIG use demonstrate
that liquid nicotine concentration and device power setting alone and in combination influence
puffing behavior during use of ECIGs containing protonated nicotine. Additionally, the observed
differences in puff topography may be influenced by direct effects of nicotine and/or other
sensations associated with ECIG use (e.g., harshness), suggesting that the effects of liquid
concentration and/or device power on puff topography may be moderated by subjective effects.
Subjective Effects
In this study, subjective effects involved measurement of abstinence symptom severity,
the direct effects of nicotine, and the direct effects of ECIG use. Additionally, this study
measured specific sensations associated with ECIG product use (via the gLMS). Overall,
significant differences were observed on measures of abstinence symptom severity, the direct
effects of nicotine (see Table 2), and the direct effects of ECIG use (see Table 6). Also,
significant differences were observed in all gLMS items (see Tables 7 and 8). These differences
indicate that liquid nicotine concentration and device power influenced the subjective profile of
ECIGs containing protonated nicotine.
Following the directed use period, all abstinence symptoms (i.e., Hughes-Hatsukami
items) were reduced, with significant reductions observed on some VAS items. Significant
reductions in abstinence symptom ratings following the directed use period (i.e., 10 puffs, 30 sec
IPI) were observed in all conditions for the items assessing “Craving,” “Impatient,” and “Urges
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to vape/smoke.” With respect to how liquid nicotine concentration influenced craving ratings,
following the directed use period (i.e., 10 puffs, 30 sec IPI), within the 15 W conditions, the
mean reduction in craving ratings was more pronounced (but not significantly so) in the 30
mg/ml nicotine condition (M=32.5, SD=32.8) when compared to the 10 mg/ml nicotine
condition (M=25.7, SD=25.6). This observation that higher liquid nicotine concentration is
associated with more pronounced reduction in craving ratings is consistent with previous studies
of freebase nicotine ECIG liquids (Dawkins et al., 2018). Specifically, increases in liquid
nicotine concentration were associated with significantly more pronounced reduction in craving
ratings (Hiler et al., 2017, 2020). Examining the effect of device power setting (independent of
liquid nicotine concentration), within the 10 mg/ml nicotine condition, the observed mean
reduction in craving ratings was more pronounced (but not significantly so) in the 30 W
condition (M=30.9, SD=26.8) when compared to the 15 W condition (M=25.7, SD=25.6). This
observation that greater device power output is associated with more pronounced reduction in
craving ratings is consistent with previous studies of ECIGs. Specifically, increases in device
power output were associated with significantly more pronounced reduction in craving ratings
(Hiler et al., 2020). Looking at the combined effects of liquid nicotine concentration and device
power output, in the condition with highest liquid nicotine concentration and higher device
power setting (30 mg/ml;30 W), the mean (SD) reduction in craving ratings following 10 puffs
was 51.6 (27.5), the greatest reduction in craving ratings observed following the directed use
period (see Figure 5; p. 72). Additionally, the mean reduction in craving ratings observed in the
30 mg/ml;30 W condition was significantly more pronounced when compared to the reduction
observed in the 10 mg/ml;15 W condition [(M=25.7, SD=25.6); t(20)=-3.5, p<0.05]. Similar
effects were observed after the directed use period for items “Impatient” and “Urges to
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vape/smoke.” In sum, these observations that ratings of abstinence symptoms were reduced
following 10 puffs demonstrate that liquid nicotine concentration and device power setting alone
and in combination influence the abstinence symptom suppression of ECIGs containing
protonated nicotine.
Significant differences were observed for items that measured the direct effects of
nicotine and the direct effects of ECIG use. Significant increases in ratings of the direct effects of
nicotine were observed following the directed use period (i.e., 10 puffs, 30 sec IPI) for the items
“Dizzy” and “Nauseous.” Examining the effect of device power setting (independent of liquid
nicotine concentration), significant increases in mean “Dizzy” ratings following the directed use
period were observed within the 30 W conditions only. Looking at the combined effects of liquid
nicotine concentration and device power output, in the condition with highest liquid nicotine
concentration and higher device power setting, a significant increase in nauseous ratings
following the directed use period was observed in the 30 mg/ml;30 W condition only. These
observations that higher liquid nicotine concentration and increased device power output are
associated with increased ratings of the direct effects of nicotine are consistent with previous
studies of ECIGs. Specifically, increases in one or both of these factors were associated with
significant increases in ratings of the direct effects of nicotine (Hiler et al., 2017, 2020; Dawkins
et al., 2018).
Similar effects based on liquid nicotine concentration and/or device power output were
observed for the direct effects of ECIG use items “Did the e-cig make you dizzy?” (within the
ECIG user group only; see Group Differences) and “Did the e-cig reduce your hunger for food?”
following the directed use period. Interestingly, ratings of “Was the e-cig satisfying?” were
significantly greater in the 10 mg/ml;30 W condition (M=65.0, SEM=5.3) when compared to the
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10 mg/ml;15 W condition (M=51.9, SEM=5.3) following the ad lib use period. A similar effect
was observed for the item “Did the e-cig taste good?”, suggesting that device power output
influenced ECIG palatability at lower liquid nicotine concentrations. In sum, these observations
that increases in the direct effects of nicotine and the direct effects of ECIG use ratings increased
as liquid nicotine concentration and device power output increased demonstrate that both of
these factors, alone and in combination, influence the direct effects of ECIGs containing
protonated nicotine.
Significant differences in specific sensations associated with ECIG use (i.e., flavor
sensation, harshness, and throat hit) based on liquid nicotine concentration and device power
setting were observed. For example, significant differences in mean ratings of “Harshness” based
on liquid nicotine concentration and device power setting condition were observed following
both ECIG use periods. With respect to how liquid nicotine concentration influenced craving
ratings, following the ad lib use period, within the 15 W conditions, mean harshness ratings were
significantly greater in the 30 mg/ml nicotine condition (M=32.4, SEM=6.0) when compared to
the 10 mg/ml nicotine condition (M=16.4, SEM=4.1). Examining the effect of device power
setting (independent of liquid nicotine concentration), within the 10 mg/ml nicotine condition,
observed mean harshness ratings were significantly greater in the 30 W condition (M=27.7,
SEM=5.6) when compared to the 15 W condition (M=16.4, SEM=4.1). Looking at the combined
effects of liquid nicotine concentration and device power output, in the condition with highest
liquid nicotine concentration and higher device power setting (30 mg/ml;30 W), mean (SD)
harshness ratings were 38.0 (5.9), the highest ratings of harshness observed following the ad lib
period (see Figure 26; p. 124). Additionally, mean harshness ratings exceeded the “Strong” label
in the 30 mg/ml;30 W condition only. These observations that higher liquid nicotine
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concentration and greater device power output are associated with greater sensation ratings are
consistent with previous studies of ECIGs (Dawkins et al., 2016; Hiler et al., 2020). Similar
effects were observed in gLMS items “flavor sensation” and “throat hit.” In sum, these
observations of increased ratings of sensations associated with ECIG use as liquid nicotine
concentration and device power setting were increased demonstrate that both of these factors,
alone and in combination, influence the specific sensations of ECIGs containing protonated
nicotine.
Furthermore, the observed differences in subjective effects may be an influence on puff
topography. Specifically, higher liquid concentration and greater device power output was
associated with increased ratings of “Dizzy,” “Nauseous,” and “Harshness.” These results
suggest that liquid concentration and device power influence user experience, with increased
subjective ratings as these factors are increased. Significant decreases in puff duration followed a
similar pattern, with observations of decreased puff duration as liquid concentration and device
power were increased. As users experience more pronounced direct effects and sensations
associated with ECIG use, a decrease in puff duration may be adopted in response to sensation
changes (i.e., harshness) and/or in an effort to titrate nicotine dose.
Considered together, these observations of changes in abstinence symptom severity, the
direct effects of nicotine, the direct effects of ECIG use, and specific sensations associated with
ECIG use demonstrate that liquid nicotine concentration and device power setting alone and in
combination influence the subjective profile of ECIGs containing protonated nicotine.
Additionally, the influence of these factors on subjective profile may moderate the changes
observed in puff topography. Specifically, puffing behavior may be adjusted in response to
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changes in specific sensations associated with ECIG use (due to increased harshness) and/or in
response to the direct effects of nicotine/ECIG use (in an effort to titrate dose).
Group Differences
Participants were separated into two distinct groups based on experience with ECIGs
(ECIG users, N=11; ECIG naïve cigarette smokers, N=10), and differences between these groups
were observed for some measures. Overall, significant group differences were observed in puff
topography (e.g., puff duration) and subjective measures (e.g., “heart pounding” and “did the ecig make you dizzy?”), indicating that experience with ECIGs may influence puffing behavior
and subjective effects. Specifically, ECIG users took significantly longer puffs than cigarette
smokers in all conditions during the ad lib use period. This effect is consistent with research on
ECIGs containing freebase nicotine (Farsalinos et al., 2015; Hiler et al., 2017). Also, ECIG users
took fewer puffs (though not significantly so) than cigarette smokers, possibly providing an
explanation for the lack of group differences in plasma nicotine concentration. Additionally,
significant differences between groups were observed pre-directed use period for some
subjective items (i.e., difficulty concentrating, irritability, lightheaded), suggesting differences in
abstinence symptom severity and thus, potentially, dependence level (i.e., greater abstinence
symptom severity at baseline may reflect more dependence). However, groups did not
significantly differ on measures of nicotine dependence (see Table 1, p. 46). Significant group
differences were observed following the directed use period for some items measuring the direct
effects of nicotine and ECIG use (i.e., heart pounding and “did the e-cig make you dizzy?”).
Specifically, mean ratings of heart pounding and dizziness were significantly greater in the ECIG
users compared to the cigarette smokers following the directed use period (i.e.,10 puffs). This
effect is consistent with research on ECIGs containing freebase nicotine (Hiler et al., 2017).
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These observations indicate that experience with ECIGs is associated with changes in puffing
behavior, as well as changes in the subjective profile of ECIGs. Importantly, significant group
differences were not observed in plasma nicotine concentration or HR following ECIG use.
Unfortunately, the present study was not powered adequately to examine group differences, and
further examination of the effect of experience with ECIGs on the physiological and subjective
effects of ECIGs containing protonated nicotine is warranted, including dependence level as
assessed by abstinence symptom severity during periods where no nicotine self-administration is
permitted.
Limitations
There are several limitations in the present study. First, this study was not designed to
examine differences between groups based on experience with ECIGs, gender, or flavor
preference. Differences between groups based on ECIG experience were detected, but this study
may have lacked sensitivity to characterize fully differences based on participants’ prior ECIG
experience. Additionally, this study may have lacked sensitivity to detect differences based on
participant demographics or flavor preference. Future studies would benefit from larger sample
sizes in order to detect potential differences based on participant characteristics. Additionally,
examinations of flavor preference in future studies may benefit from the inclusion of an
unflavored liquid as a placebo control.
Second, the use of a single variable wattage ECIG device (Kanger Sub Box Mini) in this
study may not be indicative of the typical device used by experienced ECIG users. In fact, the
most popular ECIG device type used in the US is the “pod mod.” However, characteristics of
ECIG devices vary widely (e.g., battery voltage, liquid composition, wick material), and the
majority of “pod mod” ECIGs do not allow the power of the device to be changed/manipulated.
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The use of one variable wattage device was necessary to minimize potential threats to internal
validity, ensuring that device characteristics (besides those being examined, e.g., power setting)
were unlikely to influence study results. Future studies would benefit from examining the
influence of additional device characteristics (e.g., liquid composition, wick material; see Karam
et al., 2021; Talih et al., 2020) on the nicotine delivery and subjective profile of ECIGs.
Third, the absence of a freebase nicotine condition does not allow a direct comparison to
protonated nicotine at different liquid nicotine concentrations and device power settings. This
limitation is important considering the subjective outcomes (e.g., harshness), as protonated
nicotine is often characterized as a less harsh alternative to freebase nicotine, especially at higher
concentrations (Duell et al., 2020; Henningfield et al., 2004; Pankow, 2001). However, past
research on ECIGs has been conducted primarily using freebase nicotine, as the vast majority of
ECIG liquids contained freebase nicotine until the introduction of JUUL to the US marketplace
in 2015 (Duell et al., 2020; Jackler & Ramamurthi 2019). Future studies would benefit from
including freebase nicotine condition(s) as a direct comparison to protonated nicotine to further
characterize the influence of nicotine protonation in liquids used with ECIG devices.
Finally, the laboratory setting may limit the generalizability of the present study. Future
studies of protonated nicotine would benefit from naturalistic observations and ambulatory data
collection to improve external validity.
Conclusions
This clinical laboratory study examined the influence of liquid nicotine concentration and
device power setting on the physiological and subjective effects of ECIGs containing protonated
nicotine. This study also included a preliminary examination of the extent to which experience
with ECIGs influenced these outcome measures. The results demonstrated that the nicotine
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delivery profile of ECIG products containing protonated nicotine is influenced by the nicotine
concentration in the liquid, the power of the device, user experience and user behavior. Overall,
plasma nicotine concentration was greatest in the highest liquid nicotine and device power
condition (30 mg/ml;30 W) following ten puffs. Following the ad lib use period, significant
differences in plasma nicotine concentration were not revealed across liquid nicotine
concentration or device power setting. The influence of user experience (subjective profile) and
user behavior (puff topography) may explain the absence of an effect of liquid concentration
and/or device power following the ad lib use period. Specifically, decreased puff count and
duration may have been adopted in order to titrate nicotine dose and/or in response to increased
ratings of harshness. The interaction of ECIG device characteristics (e.g., liquid concentration
and device power) and subsequent subjective profile and user behavior is an essential
consideration for stakeholders interested in seeing ECIGs regulated effectively.
The nicotine delivery profile of ECIG products is influenced by the nicotine
concentration in the liquid, the power of the device, user experience and user behavior.
Importantly, these factors can influence one another, as evidenced by the changes in puff
duration in conditions rated as more harsh in this study. For this reason, all these factors are
important components in determining ECIG nicotine delivery to users’ blood and brain and
should be considered integral when considering effective ECIG regulations. Regulations
comprised of an upper limit of liquid nicotine concentration (as in the EU; Kennedy et al., 2017)
aim to limit the nicotine delivery and, further, reduce the abuse liability of ECIGs. However, the
present findings suggest that nicotine delivery is influenced at least as much by device power as
by liquid concentration. Additionally, puff duration can impact the nicotine delivery profile of
ECIGs directly, suggesting that comprehensive regulations must include limits on puff duration.
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Importantly, limiting puff duration is already a characteristic of popular ECIG products (JUUL,
limit of 5.9 seconds; Karam et al., 2021). The results of the present study make clear that puff
duration limits by themselves may not be effective in controlling nicotine delivery to the user
and also highlight that a 5.9 sec duration limit is likely too long, as most participants took puffs
that were much shorter. In order to construct comprehensive and effective ECIG regulations, the
factors that influence nicotine delivery must be considered together; one way in which this can
be achieved is combining regulations targeting nicotine flux (the rate at which nicotine is emitted
from the ECIG; Eissenberg et al., 2020) and regulations that limit puff duration. By limiting
nicotine emission rate and puff duration simultaneously, regulators may hope to gain control
over the maximum dose of nicotine ECIG users can self-administer with each puff, independent
of the nicotine concentration of the liquid and the form of the nicotine in the liquid (freebase vs
protonated).
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Appendix A

Hughes-Hatsukami Withdrawal VAS Scale (Hughes & Hatsukami, 1986).

These phrases may or may not describe how you feel right now. Please
respond to each word or phrase with how you feel RIGHT NOW.

Not at all
1. Urges to use a cigarette
2. Irritability/frustration/anger
3. Anxious
4. Difficulty concentrating
5. Restlessness
6. Hunger
7. Impatient
8. Craving a cigarette/nicotine
9. Drowsiness
10. Depression/feeling blue
11. Desire for sweets

Extremely
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Appendix B
Direct Effects of Nicotine Scale
These phrases may or may not describe how you feel right now. Please
respond to each word or phrase with how you feel RIGHT NOW.

Not at all
12. Nauseous
13. Dizzy
14. Lightheaded
15. Nervous
16. Sweaty
17. Headache
18. Excessive salivation
19. Heart pounding
20. Confused
21. Weak

Extremely
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Appendix C
General Labeled Magnitude Scale
For each item, please indicate how you would describe the ECIG you just used by placing a mark
on the vertical numbered line.

How would you describe
the overall flavor
sensation of the ECIG you
just used?
Strongest Imaginable
Sensation of Any
Kind

Very Strong

Strong

Moderate
Weak
Barely Detectable
No Sensation

Please specify the number
you indicated with the
horizontal line

